Pharmacy Drug Policy

SUBJECT: Inflammatory Conditions Clinical Review Prior Authorization (CRPA) Rx & Medical Drugs
POLICY NUMBER: PHARMACY-73
EFFECTIVE DATE: 01/01/2018
LAST REVIEW DATE: 11/19/2026

If the member's subscriber contract excludes coverage for a specific service or prescription drug, it is not covered under that contract. In such cases, medical or drug policy criteria are not applied. This drug policy applies to the following line/s of business:

Policy Application

Category:	☒ Commercial Group (e.g., EPO, HMO, POS, PPO)	☒ Medicare Advantage
	☒ On Exchange Qualified Health Plans (QHP)	☐ Medicare Part D
	☒ Off Exchange Direct Pay	☒ Essential Plan (EP)
	☒ Medicaid & Health and Recovery Plans (MMC/HARP)	☒ Child Health Plus (CHP)
	☐ Federal Employee Program (FEP)	☐ Ancillary Services
	☒ Dual Eligible Special Needs Plan (D-SNP)	

DESCRIPTION:

The Inflammatory Conditions Clinical Review Prior Authorization (CRPA) is designed to ensure that newly approved (FDA) prescription drugs are used appropriately in cases where a drug poses potential efficacy, quality, toxicity, or utilization concerns for members of the Health Plan. In addition, this policy may be used for medications that have significant concerns about safety or inappropriate use, but do not warrant a stand-alone policy. The Pharmacy Management clinical team reviews the drugs falling into these categories under the process of Clinical Review Prior Authorization (CRPA). A Letter of Medical Necessity (LOMN), Exception Form, or Prior Authorization Form completion is required for consideration of drug coverage under this policy.
Please note that certain medications to treat inflammatory conditions that have multiple indications are not contained within this policy and have a stand-alone policy: Cimzia, Enbrel, adalimumab, infliximab products, ustekinumab.

CURRENT INFLAMMATORY CONDITIONS CRPA RX AND MEDICAL DRUGS:

DRUG NAME – generic name (Medical/Rx Benefit)

Authorization Criteria

Actemra - tocilizumab (Medical or Rx)
Avtozma -tocilizumab-anoh (Medical or Rx)
Tofidence tocilizumab-bavi (Medical)
Tyenne – tocilizumab-aazg (Medical or Rx)

1. The patient must have a diagnosis of moderately to severely active **Rheumatoid Arthritis**
   a. Must be prescribed by or in consultation with a Rheumatologist **AND**
   b. The patient must be at least 18 years of age **AND**
   c. Must have failed to respond to and/or is intolerant to approved disease-modifying antirheumatic drug (DMARD) agents, such as methotrexate, azathioprine, sulfasalazine, or hydroxychloroquine, either alone or in combination for a 3-month period
      i. Patients starting on Actemra concurrently with methotrexate, sulfasalazine, or leflunomide will not be subject to the above requirement. **AND**
   d. The patient must meet one of the following:
      i. Treatment with **IV tocilizumab (Actemra, Avtozma, Tofidence or Tyenne)** will require:
         a) Documentation of an inability to self-inject
            I. Applies to New Starts of all lines of business

II. Applies to Existing Users for all non-Medicare Part B lines of business **AND**
b) Failure or serious side effects with Inflectra/Avsola or Simponi Aria
I. Applies to New Starts of all lines of business
ii. IV tocilizumab dosing for adults with rheumatoid arthritis is:
I. Initial dosing will be limited to 4 mg/kg every 4 weeks
II. After 12 weeks, based on clinical response, dose can be increased to 8 mg/kg but the total dose cannot exceed 800 mg
iii. Treatment with **Actemra SC or Tyenne SC** will require failure or serious side effects with Humira/Simlandi/Hadlima
iv. Treatment with **Avtozma SC** will require failure or serious side effects with Humira/Simlandi/Hadlima AND either Actemra SC or Tyenne SC
v. **SC tocilizumab** dosing for adults with rheumatoid arthritis is:
I. Patients less than 100 kg should receive 162 mg every other week. Dosing can be increased to weekly based on clinical response.
II. Patients at or above 100 kg should receive 162 mg every week
III. Quantity limit of 4 syringes per 28 days

2. The patient must have a diagnosis of moderately to severely active **Polyarticular Juvenile Idiopathic Arthritis (pJIA)** in children 2 years of age or older
   a. Must be prescribed by or in consultation with a Rheumatologist **AND**
   b. Must have a contraindication to have failed to respond to, or must be intolerant to treatment with a disease-modifying antirheumatic drug (DMARD) (such as methotrexate, leflunomide, sulfasalazine), NSAID, analgesic, or corticosteroid
      i. Patients starting on SC tocilizumab (Actemra or Tyenne) concurrently with methotrexate, sulfasalazine, or leflunomide will not be subject to the above requirement
   c. The patient must meet one of the following:
      i. Treatment with **Actemra SC or Tyenne SC** will require failure or serious side effects with Humira/Simlandi/Hadlima
      ii. Treatment with **Avtozma SC** will require failure or serious side effects with Humira/Simlandi/Hadlima AND either Actemra SC or Tyenne SC
      iii. Treatment with **IV tocilizumab (Actemra, Avtozma, Tofidence or Tyenne)** will require:
         a) Documentation of an inability to self-inject
            I. Applies to New Starts of all lines of business
            II. Applies to Existing Users for all non-Medicare Part B lines of business **AND**
         b) Failure or serious side effects with Simponi Aria for a diagnosis of pJIA
            I. Applies to New Starts of all lines of business
   d. IV tocilizumab dosing for children with pJIA is:
      I. Patients less than 30kg should receive 10mg/kg every 4 weeks
      II. Patients at or above 30kg should receive 8mg/kg every 4 weeks
   e. SC tocilizumab dosing for children with pJIA is:
      I. Patients less than 30kg should receive 162mg every 3 weeks
      II. Patients at or above 30kg should receive 162mg every 2 weeks
3. The patient must have a diagnosis of Active **Systemic Juvenile Idiopathic Arthritis (sJIA)** in children 2 years of age or older
   a. Must be prescribed by or in consultation with a Rheumatologist **AND**
   b. Must have a contraindication to have failed to respond to, or must be intolerant to treatment with a disease-modifying antirheumatic drug (DMARD) (such as methotrexate, leflunomide, sulfasalazine), NSAID, analgesic, or corticosteroid
      i. Patients starting on SC tocilizumab (Actemra or Tyenne) concurrently with methotrexate, sulfasalazine, or leflunomide will not be subject to the above requirement
   c. The patient must meet one of the following:

i. Treatment with **Avtozma SC** will require failure or serious side effects with either Actemra SC or Tyenne SC
ii. Treatment with **IV tocilizumab (Actemra, Avtozma, Tofidence or Tyenne)** will require:
a) Documentation of an inability to self-inject
I. Applies to New Starts of all lines of business
II. Applies to Existing Users for all non-Medicare Part B lines of business

d. IV tocilizumab dosing for children with sJIA is:
I. Patients less than 30kg should receive 12mg/kg every 2 weeks
II. Patients at or above 30kg should receive 8mg/kg every 2 weeks

e. SC tocilizumab dosing for children with sJIA is:
I. Patients less than 30kg should receive 162mg every 2 weeks
II. Patients at or above 30kg should receive 162mg once every week

4. The patient must have a diagnosis of **giant cell arteritis (GCA)**
   a. The patient must be at least 18 years of age and have a confirmed diagnosis of giant cell arteritis, and the drug prescribed by or in consultation with an Ophthalmologist, Neurologist, or Rheumatologist
   b. Treatment with **Avtozma SC** will require failure or serious side effects with either Actemra SC or Tyenne SC
   c. SC tocilizumab dosing for adults with GCA is:
      i. 162mg given once every week as a subcutaneous injection, in combination with a tapering course of glucocorticoids
      ii. A dose of 162 mg given SC every other week, in combination with a tapering course of glucocorticoids, may be prescribed based on clinical considerations
      iii. Quantity limit of 4 syringes per 28 days
   d. IV tocilizumab dosing for adults with GCA is:
      i. 6 mg/kg every 4 weeks as an intravenous infusion, in combination with a tapering course of glucocorticoids
      ii. Doses exceeding 600 mg per infusions are not recommended in GCA patients
5. The patient must have a diagnosis of **systemic sclerosis- associated interstitial lung disease (SSc-ILD) with declining pulmonary function**
   a. The patient must be ≥ 18 years of age **AND**
   b. Must be prescribed by or in consultation with a Rheumatologist or Pulmonologist **AND**
   c. The patient must have lung fibrosis based on a HRCT scan from within the last 12 months **AND**
   d. Forced vital capacity (FVC) is > 55% of the predicted value; **AND**
   e. The patient must have been treated with mycophenolate mofetil (MMF)
   f. Actemra SC is the only FDA approved tocilizumab for adults with SSc-ILD to be given 162 mg once every week as a subcutaneous injection
   g. IV tocilizumab is not approved for SSc-ILD with declining pulmonary function
   h. Quantity Limit of 4 syringes per 28 days
6. IV tocilizumab (Actemra, Actozma, Tofidence or Tyenne) will be covered for use with chimeric antigen receptor (CAR) T-Cell therapy for potential severe or life-threatening cytokine-release syndrome (CRS)
7. IV tocilizumab/Actemra/Actozma/Tofidence/Tyenne, have been FDA approved for the treatment of hospitalized adult patients, and **Actemra/Tyenne/Tofidence** with additional indication for pediatric patients (2 years of age or older), with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) for inpatient use only; therefore, coverage in the outpatient setting will not be authorized.

HCPCS:
J3262 (Actemra), J3590 & Q5135 (Tyenne), J3590 (Tofidence), Q0237 & Q5156 (Avtozma)

Bimzelx - bimekizumab (Rx)

1. The patient must be at least 18 years of age **AND**
   a. Must have moderate to severe chronic **Plaque Psoriasis** that involves at least 10% of their body surface area. Consideration will be given to those who have less than 10% body surface area involvement but have severe disease of sensitive areas or areas causing significant disruption in normal activities (such as the hands, feet, face, genitalia) **AND**
      i. Must be prescribed by or in consultation with a Dermatologist or Rheumatologist **AND**
         a) The patient must be a candidate for systemic therapy or phototherapy and meet for **ONE** of the following (**A or B**)
            A. The patient must have had a 3-month trial of systemic therapy (i.e., acitretin, methotrexate, or cyclosporine) that resulted in an inadequate response (failure). A 3-month trial will not be required if the member experienced serious side effects during a trial of one of the aforementioned agents **OR**
            B. The patient must have had a 3-month trial of Ultraviolet B (UVB) Phototherapy or Psoralen Ultraviolet A (PUVA) Phototherapy that resulted in an inadequate response (failure) **AND**
         b) The patient must also have a documented drug failure or serious side effects to **TWO** of the following: Humira/Simlandi/Hadlima, Otezla/XR, Sotyktu, Selarsdi/Yesintek SC, Skyrizi, Tremfya, Cosentyx, Enbrel
         c) Documentation of a baseline Psoriasis Area Severity Index (PASI) score is required
         d) Coverage for Bimzelx will only be authorized under the pharmacy benefit
         e) Initial approval will be for 1 year. Initial recertification will require documentation that the patient achieved PASI 90 (almost clear skin) after the 16-week induction dosing was complete AND has maintained PASI 90. Initial recertification will be approved for 1 year. Ongoing recertifications will require documentation that the patient has maintained PASI 90 and will be approved for 1 year.
         f) Approved Dosing:
            I. Induction: 320 mg at week 0, week 4, week 8, week 12, and week 16
            II. Maintenance: 320 mg every 8 weeks starting at week 24
               1. For patients that weigh 120 kilograms (kg) or more, a dose of 320 mg every 4 weeks (2 mL/28 days) may be considered after at least 32 weeks of treatment (including 16 weeks induction and at least 16 weeks of maintenance treatment) if the patient achieved PASI 90 (almost clear skin) after the 16-week induction dosing **AND** failed to maintain PASI 90 after 16 weeks (2-doses) of maintenance treatment
   b. The patient must have a diagnosis of active **Psoriatic Arthritis**
      i. Must be prescribed by or in consultation with a Rheumatologist or Dermatologist
      ii. The patient must also have a documentation drug failure or serious side effects with **TWO** of the following: Enbrel, Humira/Simlandi/Hadlima, Selarsdi/Yesintek SC, Cosentyx, Otezla/XR, Tremfya, Skyrizi, Rinvoq and Xeljanz/tofacitinib/Xeljanz XR/tofacitinib ER
      iii. Approved dosing is 160 mg once every 4 weeks
      iv. Initial approval will be for 1 year. Recertification will require documentation confirming clinical improvement in signs and symptoms of Psoriatic Arthritis and will be approved for 2 years.
   c. The patient must have a diagnosis of **Ankylosing Spondylitis**
      i. Must be prescribed by or in consultation with a Rheumatologist **AND**
      ii. Must have refractory disease defined by failure of or intolerance to at least **TWO** different NSAIDS at maximum strength for at least 1 month each **AND**

iii. The patient must also have a documentation drug failure or serious side effects with **TWO** of the following: Cosentyx, Enbrel, Humira/Simlandi/Hadlima, Rinvoq and Xeljanz/tofacitinib/Xeljanz XR/tofacitinib ER
iv. Approved dosing is 160 mg SC once every 4 weeks
v. Initial approval will be for 1 year. Recertification will require documentation confirming clinical improvement in signs and symptoms of Ankylosing Spondylitis and will be approved for 2 years.

d. The patient must have a diagnosis of **Non-Radiographic Axial Spondylitis (nr-axSpA)**
i. Must be prescribed by or in consultation with a Rheumatologist **AND**
ii. Must have refractory disease defined by failure of or intolerance to at least **TWO** different NSAIDS at maximum strength for at least 1 month each **AND**
iii. The patient must also have a documentation drug failure or serious side effects with **TWO** of the following: Rinvoq, Cimzia and Cosentyx
iv. Approved dosing is 160 mg SC once every 4 weeks
v. Initial approval will be for 1 year. Recertification will require documentation confirming clinical improvement in signs and symptoms of nr-axSpA and will be approved for 2 years

e. The patient must have a diagnosis of **Hidradenitis Suppurativa**
i. Must be prescribed by or in consultation with a Dermatologist
ii. Must be at least 18 years old
iii. Must have a diagnosis of stage II, stage III, or severe refractory hidradenitis suppurativa with recurrent abscesses
iv. Must have had a minimum of a three-month trial of systemic antibiotics (such as minocycline, doxycycline, clindamycin, or rifampin) which failed to provide clinical improvement
a) A 3-month trial will not be required if the member experienced serious side effects during a trial of one of the above-mentioned agents
v. Must have had serious side effects or drug failure of **TWO** of the following: Humira/Simlandi/Hadlima, Cosentyx
vi. Coverage for Bimzelx will only be authorized under the pharmacy benefit
vii. Quantity Limit: 1 mL (160 mg/mL injectors/syringes)/28 days

Cibinqo - abrocitinib (Rx)

1. Must be prescribed by or in consultation with an Allergist, Immunologist, or Dermatologist **AND**
2. Must be at least 12 years of age **AND**
3. Must have a diagnosis of moderate to severe atopic dermatitis
   a. Must involve at least 10% body surface area
      i. Consideration will be given to those who have less than 10% body surface area involvement but have severe disease of the hands, feet, or other sensitive areas **OR** severe itch that has been unresponsive to topical therapies **AND**
   b. Must have evidence of functional impact on everyday activities **AND**
4. Must have had a trial and failure or contraindication to:
   a. Medium to higher potency prescription topical corticosteroid therapy **AND**
      i. Adequate trial is defined as ≥ 28 days or for the maximum duration recommended by the product prescribing information (i.e., 14 days for super-potent topical corticosteroids), whichever is shorter **AND**
   b. Tacrolimus or pimecrolimus
      i. Adequate trial is defined as ≥ 6 weeks based on prescribing information **AND**
   c. Treatment with at least one of the above therapies must have occurred within the previous 6 months **AND**
5. Must have had serious side effects or drug failure of Dupixent **AND** Rinvoq

6. Initial approval will be for 6-months. Recertification will require documentation confirming clinical improvement in signs and symptoms of Atopic Dermatitis and will be approved for 2 years.
7. Cibinqo will not be approved in combination with Opzelura, Rinvoq, Dupixent, or Adbry
8. Approved dosing:
    a. 100 mg by mouth once daily
        i. If an adequate response is not achieved, consider increasing to 200 mg orally once daily. Discontinue if inadequate response after dosage increase.

Cosentyx IV & SC - secukinumab IV (Medical), SC (Rx)

1. The patient must meet for **ONE** of the following **(a,b,c,d,e):**
    a. The patient must be at least 6 years of age and have a diagnosis of moderate to severe chronic **Plaque Psoriasis** that involves at least 10% of the body surface area. Consideration will be given to those who have less than 10% body surface area involvement but have severe disease of sensitive areas or areas causing significant disruption in normal activities (such as the hands, feet, face, genitalia) **AND**
        i. Must be prescribed by or in consultation with a Dermatologist or Rheumatologist **AND**
        ii. The patient must be a candidate for systemic therapy or phototherapy and meet for **ONE** of the following (**A or B**)
            A. The patient must have had a 3-month trial of systemic therapy (i.e., acitretin, methotrexate, or cyclosporine) that resulted in an inadequate response (failure). A 3-month trial will not be required if the member experienced serious side effects during a trial of one of the aforementioned agents **OR**
            B. The patient must have had a 3-month trial of Ultraviolet B (UVB) Phototherapy or Psoralen Ultraviolet A (PUVA) Phototherapy that resulted in an inadequate response (failure)
    b. The patient must be at least 2 years of age and have a diagnosis of active **Psoriatic Arthritis AND**
        i. Must be prescribed by or in consultation with a Rheumatologist or Dermatologist
        ii. The patient must be at least 2 years of age for coverage of Cosentyx SC under the pharmacy benefit
        iii. The patient must be at least 18 years of age for coverage of Cosentyx IV under the medical benefit
    c. The patient must be at least 12 years of age and have a diagnosis of **Ankylosing Spondylitis**
        i. Must be prescribed by or in consultation with a Rheumatologist **AND**
        ii. Must have refractory disease defined by failure of or intolerance to at least **TWO** different NSAIDS at maximum strength for at least 1 month each
    d. The patient must be at least 18 years of age and have a diagnosis of **Non-Radiographic Axial Spondylitis (nr-axSpA)**
        i. Must be prescribed by or in consultation with a Rheumatologist **AND**
        ii. Must have refractory disease defined by failure of or intolerance to at least **TWO** different NSAIDS at maximum strength for at least 1 month each
    e. The patient must be at least 4 years of age and have a diagnosis of **Enthesitis-Related Arthritis (ERA)**
        i. Must be prescribed by or in consultation with a Rheumatologist **AND**
        ii. Must have failed to respond to and/or is intolerant to approved disease- modifying antirheumatic drugs (DMARDs) agents, such as methotrexate, NSAIDs, analgesics or corticosteroids either alone or in combination
    f. The patient must be at least 12 years of age and older weighing 30 kg or more and have a diagnosis of **Hidradenitis Suppurativa (HS)**
        i. Must be prescribed by or in consultation with a Dermatologist **AND**

ii. Must have a diagnosis of stage II, stage III, or severe refractory hidradenitis suppurativa with recurrent abscesses **AND**
iii. Must have had a minimum of a three-month trial of systemic antibiotics (such as minocycline, doxycycline, clindamycin, or rifampin) which failed to provide clinical improvement
a) A 3-month trial will not be required if the member experienced serious side effects during a trial of one of the above-mentioned agents

2. Intravenous (IV) Cosentyx will only be covered for the treatment of Psoriatic Arthritis, Ankylosing Spondylitis, and Non-Radiographic Axial Spondylitis
3. Approved Dosing:
   a. Pharmacy Benefit (SC): an initial loading dose of 75 mg, 150mg, 300mg subcutaneous injection at weeks 0,1,2,3, and 4, and then maintenance dosing of 75 mg, 150mg, or 300mg every 4 weeks depending on the diagnosis (please refer to the prescribing information)
      i. Treatment of Psoriatic Arthritis, Ankylosing Spondylitis, and Non-Radiographic Axial Spondylitis may be initiated with or without a loading dose
      ii. Treatment of Hidradenitis Suppurativa:
         A. Adult patients: the recommended dosing is 300mg SC injection at weeks 0,1,2,3 and 4 and every 4 weeks thereafter.
         B. Adult patients who have not adequately responded to 300 mg every 4 weeks, the dose maybe increased to 300 mg every 2 weeks
      iii. Pediatric patients 12 years and older: the recommended weight-based dosage is administered by SC injection at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter
         A. For patients ≥ 30kg and < 90kg the dose is 150mg
         B. For patients ≥ 90kg, the dose is 300mg
   b. Medical Benefit (IV): an initial loading dose of 6 mg/kg given by intravenous infusion at week 0, followed by a 1.75 mg/kg intravenous maintenance (max 300 mg per infusion) dose given every 4 weeks thereafter.
      i. Treatment of Psoriatic Arthritis, Ankylosing Spondylitis, and Non-Radiographic Axial Spondylitis may be initiated with or without a loading dose
4. Quantity limit (Pharmacy Benefit):
   a. 300 mg UnoReady® autoinjector pen (contains 1-300 mg pen) is 1 mL per 28 days
   b. 300 mg package (contains 2-150 mg pens/syringes) is 2 mL per 28 days
   c. 150 mg pen/syringe (contains 1-150 mg pen/syringe) is 1 mL per 28 days
   d. 75 mg syringe (contains 1-75 mg syringe) is 0.5 mL per 28 days

HCPCS: J3247

Entyvio IV & SC – vedolizumab IV (Medical), SC (Rx)

1. Must be prescribed by or in consultation with a Gastroenterologist **AND**
2. The patient must be at least 18 years of age **AND**
3. The patient must have one of the following diagnoses **(I or II):**
   I. The patient must have a diagnosis of moderately to severely active **Crohn's Disease AND**
      i. There must be documentation that azathioprine, 6-mercaptopurine, or methotrexate is not effective, contraindicated, or not tolerated
         a) Treatment with a biologic medication as first-line therapy will be assessed on a case-by-case basis through a letter of medical necessity and clinical progress notes based on severity of the disease (such as but not limited to enterocutaneous [perianal or abdominal] fistulas, rectovaginal fistulas, ileocolonic resection) **OR**
   II. The patient must have a diagnosis of moderately to severely active **Ulcerative Colitis**
      i. Must meet for **ONE** of the following **(A or B):**
         A. Must have tried and failed or has documented intolerance to at least ONE of the following conventional therapies for at least 3 months:

I. Thiopurines: Azathioprine/6-mercaptopurine (6-MP)
II. 5-Aminosalicylates: Sulfasalazine, Mesalamine, Olsalazine
III. IV or oral steroids - note, a 3-month trial of systemic steroid therapy will not be required

B. The patient has been diagnosed with pouchitis and has tried an antibiotic, corticosteroid enema, or mesalamine enema **AND**

4. The following requirements apply to only requests for **Entyvio Pen** (Pharmacy Benefit)
   - **A.** For patients not currently on treatment with IV Entyvio (i.e., treatment naïve, etc.), there must be serious side effects or drug failure with **TWO** of the following: Humira/Simlandi/Hadlima, Selarsdi/Yesintek, Skyrizi, Tremfya
   - **B.** For patients currently treated with IV Entyvio, provider must attest that patient is a clinical responder to the IV Entyvio induction therapy
5. Approved Dosing:
   - **A.** Intravenous (IV) Infusion: Initial dosing is 300 mg intravenously at weeks 0, 2, and 6 with maintenance dosing of 300 mg IV every 8 weeks. More frequent dosing will be considered on a case-by-case basis.
   - **B.** Subcutaneous (SC) Injection: Initial dosing is 300 mg intravenously at weeks 0 and 2 with maintenance dosing starting at week 6 with 108 mg SC every 2 weeks.
6. Entyvio Pen will be covered under the Pharmacy Benefit as it is FDA approved for self-administration.
7. Entyvio IV will be covered under the Medical Benefit as it is FDA approved to be administered by a healthcare provider

HCPCS: J3380

Ilumya – tildrakizumab-asmn (Medical)

1. Must be prescribed by or in consultation with a Dermatologist or Rheumatologist **AND**
2. The patient must be at least 18 years of age **AND (I or II)**
   - I. Must have moderate to severe chronic **Plaque Psoriasis** that involves at least 10% of their body surface area. Consideration will be given to those who have less than 10% body surface area involvement but have severe disease of sensitive areas or areas causing significant disruption in normal activities (such as the hands, feet, face, genitalia) **AND**
     - i. The patient must be a candidate for systemic therapy or phototherapy and meet for **ONE** of the following (**A or B**)
       - **A.** The patient must have had a 3-month trial of systemic therapy (i.e., acitretin, methotrexate, or cyclosporine) that resulted in an inadequate response (failure). A 3-month trial will not be required if the member experienced serious side effects during a trial of one of the aforementioned agents **OR**
       - **B.** The patient must have had a 3-month trial of Ultraviolet B (UVB) Phototherapy or Psoralen Ultraviolet A (PUVA) Phototherapy that resulted in an inadequate response (failure)
     - ii. Approved dosing for moderate-to-severe Plaque Psoriasis: Ilumya 100mg SC at weeks 0, 4 and every 12 weeks thereafter
   - II. Must have active Psoriatic Arthritis
     - i. Approved dosing for active **Psoriatic Arthritis**:
       - a. For adult patients with coexistent moderate-to-severe Plaque Psoriasis: Ilumya 100mg SC at weeks 0, 4 and every 12 weeks thereafter.
       - b. For adult patients without coexistent moderate-to-severe Plaque Psoriasis: Ilumya 100mg SC every 12 weeks
3. Coverage for Ilumya will only be authorized under the medical benefit

HCPCS: J3245

Kevzara – sarilumab (Rx)

1. The patient must have a diagnosis of moderately to severely active **Rheumatoid Arthritis**
   a. Must be prescribed by or in consultation with a Rheumatologist **AND**
   b. The patient must be at least 18 years of age **AND**
   c. Must have failed to respond to and/or is intolerant to approved disease-modifying antirheumatic drug (DMARD) agents, such as methotrexate, azathioprine, sulfasalazine, or hydroxychloroquine, either alone or in combination for a 3-month period **AND**
   d. The patient must also have a drug failure or serious side effects to **TWO** of the following agents: Actemra SC/Tyenne SC, Enbrel, Humira/Simlandi/Hadlima, Xeljanz/tofacitinib/Xeljanz XR/tofacitinib ER, Rinvoq
   e. Approved dosing is 200 mg SC once every two weeks. The weekly dose may be decreased to 150mg in patients who experience neutropenia, elevated LFTs, and/or elevated cholesterol levels on Kevzara.
2. The patient must have a diagnosis of **Polymyalgia Rheumatica (PMR)**
   a. Must be prescribed by or in consultation with a Rheumatologist **AND**
   b. The patient must be at least 18 years of age **AND**
   c. The patient must use Kevzara in combination with a tapering course of systemic corticosteroids (applicable to New Starts only) **AND**
   d. The patient must have had one of the following:
      i. An inadequate response to corticosteroids (defined as an inability to achieve remission [resolution of signs and symptoms of PMR, and normalization of CRP (<10 mg/L)] after 12 weeks of therapy) **OR**
      ii. An inability to tolerate a corticosteroid taper (defined as a recurrence of signs and symptoms of PMR during a taper attempt)
   e. Approved dosing is 200 mg SC once every two weeks
3. The patient must have a diagnosis of moderately to severely active **Polyarticular Juvenile Idiopathic Arthritis (pJIA)**
   a. Must be prescribed by or in consultation with a Rheumatologist **AND**
   b. The patient must be at least 2 years of age **AND**
   c. The patient must weigh at least 63kg **AND**
   d. Must have a contraindication to, have failed to respond to, or must be intolerant to treatment with a disease-modifying antirheumatic drug (DMARD) (such as methotrexate, leflunomide, sulfasalazine), NSAID, analgesic, or corticosteroid
      i. Patients starting on Kevzara concurrently with methotrexate, sulfasalazine, or leflunomide will not be subject to the above requirement
   e. The patient must also have a documented drug failure or serious side effects to TWO of the following agents: Actemra SC/Tyenne SC, Enbrel, Humira/Simlandi/Hadlima, Xeljanz/tofacitinib/Xeljanz XR/tofacitinib ER, Rinvoq
   f. Kevzara can be used as monotherapy or in combination with conventional DMARDs.
   g. Approved dosing is 200 mg SC once every two weeks.
4. Coverage for Kevzara will be limited to 2 syringes/28 days (2.28 mL/28 days)

Kineret - anakinra (Rx)

1. The patient must have a diagnosis of moderately to severely active **Rheumatoid Arthritis**
   a. The patient must be at least 18 years of age **AND**
   b. Must be prescribed by or in consultation with a Rheumatologist **AND**
   c. Must have failed to respond to and/or is intolerant to approved disease-modifying antirheumatic drug (DMARD) agents, such as methotrexate, azathioprine, sulfasalazine, or hydroxychloroquine, either alone or in combination for a 3-month period **AND**

d. The patient must have had drug failure or serious side effects with **TWO** of the following: Actemra SC/Tyenne SC, Enbrel, Humira/Simlandi/Hadlima, Xeljanz/tofacitinib/Xeljanz XR/tofacitinib ER, Rinvoq
e. Dosing is limited to daily subcutaneous injections (100 mg/day) **OR**

2. Kineret is also indicated for the treatment of **neonatal-onset multisystem inflammatory disease (NOMID)** as initial therapy
   a. Must be prescribed by or in consultation with a Rheumatologist, Geneticist, or a Dermatologist
   b. Initial dosing of 1mg/kg/day, maintenance dosing of 3-4 mg/kg/day and maximum dosing of 8 mg/kg/day
3. Must be used to treat patients with **deficiency of the interleukin-1 receptor antagonist (DIRA)**
   a. Must be prescribed by or in consultation with a Rheumatologist, Geneticist, Dermatologist, or a physician who specializes in the treatment of inflammatory conditions **AND**
   b. Deficiency of the interleukin-1 receptor antagonist (DIRA) must be confirmed by a mutation in the IL1RN gene **AND**
   c. Documentation of one or more of the following must be submitted:
      i Increased levels of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)
      ii Inflammatory bone disease
      iii Skin biopsy showing neutrophilic pustulosis
   d. Approval timeframe:
      i. Initial approval will be for 6 months. Recertification will require documentation of a response to treatment and will be approved for 2 years. A response to treatment is defined as any of the following:
         a) normalization of ESR and CRP
         b) resolution of inflammatory bone disease
         c) resolution of neutrophilic pustulosis
         d) reduction in the use of corticosteroids
      ii. Continued approval will require provider attestation that the patient has maintained a response to treatment and will be approved for 2 years
   e. The approved starting dose is 1 to 2 mg/kg/day with a maximum daily dose of 8 mg/kg.
      i. The allowed quantity will be reviewed in accordance with FDA-approved weight-based dosing and, as such, will be limited to the minimum number of syringes required to obtain the maximum daily dose of 8 mg/kg at the patient's current weight.
   f. Kineret should not be used in combination with Arcalyst or any other biologic product
4. Must have diagnosis of **recurrent pericarditis (RP)** defined as a subsequent pericarditis episode after a symptom-free interval of at least 4-6 weeks
   a. Must be prescribed by or in consultation with a Cardiologist **AND**
   b. Patient must be > 12 years or older **AND**
   c. Patient must be presenting with at least a second pericarditis recurrence (third pericarditis episode at minimum) despite treatment with NSAIDs, colchicine or corticosteroids, in any combination
      i. The current episode is characterized by pericardial pain for > 1 day with a numerical rating scale (NRS) pain score of > 4 **AND** a C-reactive protein level of at least of at least 1 mg/dL **OR**
      ii. The current episode must have met <u>two or more</u> of the following:
         a) Pericarditis chest pain (typically sharp chest pain, improved with sitting up and leaning forward)
         b) Pericardial rubs (superficial scratchy or squeaking sound heard with the diaphragm of a stethoscope over the left sternal border)
         c) New widespread ST-elevation or PR depression on ECG
         d) Pericardial effusion (new or worsening) **AND**

d. Provider must attest that the patient will attempt to taper and discontinue NSAIDs, colchicine and/or corticosteroids while on Kineret **AND**
e. Kineret will not be approved for patients with pericarditis secondary to tuberculosis, post-thoracic blunt trauma, myocarditis, systemic autoimmune diseases (excluding Still's disease), or neoplastic, purulent, or radiation etiologies **AND**
f. Kineret will not be approved for patients with incessant or chronic pericarditis **AND**
g. Patient is not on concurrent therapy with any of the following – Ilaris, Arcalyst, or any other biologic product
h. The maximum dose is 100 mg/day based on currently available literature
i. Approval timeframes:
    i. Initial approval of Kineret for recurrent pericarditis will be for 3 months.
    ii. Initial and subsequent recertification will require documentation that the patient has had no pericarditis recurrence while using Kineret **AND** documentation that NSAIDs, colchicine and/or corticosteroid doses have been reduced or discontinued. Initial and subsequent recertifications will be approved for 6 months at a time.

5. Quantity Limit: 30 syringes per 30 days

Lisraya (brepocitinib)-Rx

1. Must be prescribed by or in consultation with a Dermatologist or Rheumatologist **AND**
2. Must be at least 18 years of age **AND**
3. Must have a diagnosis of dermatomyositis (DM) as defined by the following: **A OR B**
    A. **Classic dermatomyositis (DM): a AND b**
        a. The presence of characteristic skin changes is confirmed by ***ONE*** of the following:
            i. Gottron's papules/sign and heliotrope rash
            ii. At least two characteristic DM skin changes including but not limited to: periorbital edema, V sign, shawl sign, holster sign, calcinosis.
            iii. A positive skin lesion biopsy confirming DM
        b. Symmetrical proximal muscle weaknesses of areas (such as extremities or neck flexors) **OR** elevated muscle-specific enzymes indicating myopathies (i.e. creatine kinase (CK) or aldolase), **AND (i OR ii)**
            i. Positive DM-specific autoantibody (MSA) testing: Mi-2, TIF1, MDA5, NXP2, SAE, or antisynthetase antibodies and SRP/HMGCR when clinically indicated
            ii. Additional testing confirming active muscle involvement (i.e. MRI, muscle biopsy, EMG etc.)
    B. **Clinically amyopathic dermatomyositis (CADM)**:
        a. The presence of characteristic skin changes confirmed by the following: **i AND ii**
            i. Gottron's papules/sign and heliotrope rash **OR** at least two characteristic DM skin changes including but not limiting to: periorbital edema, V sign, shawl sign, holster sign, calcinosis.
            ii. A positive skin lesion biopsy confirming DM
4. Documentation of non-smoking status including **EITHER** of the following:
        i. Patient is never a smoker; **OR**
        ii. Patient has not smoked in the preceding 6 months as evidenced by blood cotinine lab results of < 10ng/mL
5. Provider must attest the absence of the following:
        a. Dermatomyositis with end-stage organ involvement
        b. Dermatomyositis with irreversible muscle involvement
        c. History of:
            i. Any lymphoproliferative disorder
            ii. Active or history of cancer within 5 years prior to the request (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid carcinoma.)
            iii. Cancer-associated dermatomyositis

d. Overlap myositis/connective tissue disease (except for overlap with Sjögren's syndrome)
6. Must have had an inadequate response to IVIG
7. Must be on stable dose(s) of guideline recommended standard of care therapies including but not limiting to a corticosteroid or a conventional DMARD (i.e. methotrexate injection, mycophenolate mofetil, cyclosporine, etc.), with or without an antimalarial drug (i.e. hydroxychloroquine)
8. Lisraya will not be approved for use in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs for the treatment of dermatomyositis
9. Initial approval is 6 months
   a. Recertification is 1 year and requires documentation of clinical improvements or stabilization of impacted skin, muscle or organs

Quantity Limit: 30 tablets per 30 days

Olumiant – baricitinib (Rx)

1. Must be prescribed by or in consultation with a Rheumatologist **AND**
2. The patient must be at least 18 years of age **AND**
3. The patient must have a diagnosis of moderately to severely active **Rheumatoid Arthritis AND**
   a. Must have failed to respond to and/or is intolerant to approved disease-modifying antirheumatic drug (DMARD) agents, such as methotrexate, azathioprine, sulfasalazine, or hydroxychloroquine, either alone or in combination for a 3-month period **AND**
   b. The patient must have had failure or had serious side effects to **TWO** of the following: Actemra SC//Tyenne SC, Enbrel, Humira/Simlandi/Hadlima, Xeljanz/tofacitinib/Xeljanz XR/tofacitinib ER, Rinvoq
   c. Approved dosage is 2 mg once daily
4. The use of Olumiant for the treatment of **alopecia** (including but not limited to alopecia areata, alopecia universalis) is considered a cosmetic use (defined as use to improve a patient's appearance and/or self-esteem).
   a. For Commercial/Exchange/Essential Plan/Child Health Plus, the use of a drug, whether it is for a Food and Drug Administration (FDA) approved or off-label indication, for a cosmetic use is considered not medically necessary
5. Quantity Limit: 30 tablets per 30 days.
6. The use of Olumiant (baricitinib) for the treatment of hospitalized adults and pediatric patients (2 years of age or older) with COVID-19 who require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) is intended for inpatient use only; therefore, coverage in the outpatient setting will not be authorized. Note, this indication has not been approved by the Food and Drug Administration (FDA) for patients 2 years of age to less than 18 years of age and is only available for use under an emergency use authorization (EUA).

Omvoh - mirikizumab-mrkz (Rx)

1. Must be prescribed by or in consultation with a Gastroenterologist **AND**
2. The patient must be at least 18 years of age **AND**
   a. The patient must have a diagnosis of moderately to severely active **Ulcerative Colitis AND**
      i. Must meet for **ONE** of the following **(A or B):**
         A. Must have tried and failed or has documented intolerance to at least **ONE** of the following conventional therapies for at least 3 months:
            I. Thiopurines: Azathioprine/6-mercaptopurine (6-MP)
            II. 5-Aminosalicylates: Sulfasalazine, Mesalamine, Olsalazine
            III. IV or oral steroids - note, a 3-month trial of systemic steroid therapy will not be required
         B. The patient has been diagnosed with pouchitis and has tried an antibiotic, corticosteroid enema, or mesalamine enema **AND**

ii. The patient must have had serious side effects or drug failure of **TWO** of the following: Humira/Simlandi/Hadlima, Selarsdi/Yesintek, Skyrizi, Tremfya
iii. Approved Dosing:
a) Induction: 300 mg administered by intravenous (IV) infusion at week 0, week 4, and week 8
I. Prior Authorization of the IV induction dose is required for all lines of business under the medical benefit except Managed Medicaid
b) Maintenance: 200 mg administered by subcutaneous (SC) injection (given as two consecutive injections of 100 mg each) every 4 weeks starting at week 12

b. The patient must have a diagnosis of moderately to severely active **Crohn's Disease AND**
i. There must be documentation that azathioprine, 6-mercaptopurine, or methotrexate is not effective, contraindicated, or not tolerated
ii. Treatment with a biologic medication as first-line therapy will be assessed on a case-by-case basis through a letter of medical necessity and clinical progress notes based on severity of the disease (such as but not limited to enterocutaneous [perianal or abdominal] fistulas, rectovaginal fistulas, ileocolonic resection)
iii. The patient must have had serious side effects or drug failure of **TWO** of the following: Humira/Simlandi/Hadlima, Selarsdi/Yesintek, Skyrizi, Tremfya
iv. Approved Dosing:
a) Induction: Week 0, Week 4, and Week 8: Infuse 900 mg intravenously over at least 90 minutes.
I. Prior Authorization of the IV induction dose is required for all lines of business under the medical benefit except Managed Medicaid
b) Maintenance: Week 12 and every 4 weeks thereafter: 300 mg subcutaneous (SC) injection (given as two consecutive injections of 100 mg and 200 mg in any order).
I. The 200 mg/2 mL prefilled pen and prefilled syringe are only for maintenance treatment of Crohn's disease.

3. Quantity Limit (Pharmacy Benefit): 2 mL (2-100 mg/mL pens or 1- 200mg/2mL pen/syringe)/28 days
HCPCS: J2267

Orencia IV & SC – abatacept IV (Medical), abatacept SC (Rx)

1. The patient must have a diagnosis of moderately to severely active **Rheumatoid Arthritis**
a. The patient must be at least 18 years of age **AND**
b. Must be prescribed by or in consultation with a Rheumatologist **AND**
c. Must have failed to respond to and/or is intolerant to approved disease-modifying antirheumatic drug (DMARD) agents, such as methotrexate, azathioprine, sulfasalazine, or hydroxychloroquine, either alone or in combination for a 3-month period **AND**
d. The patient must meet **ONE** of the following:
i. **If healthcare provider administers**, treatment with IV Orencia will require failure or serious side effects with of Inflectra/Avsola or Simponi Aria
a) Applies to all lines of business
ii. **If self-administered**
a) Treatment with SC Orencia will require documentation of drug failure or serious side effects of **TWO** of the following agents: Actemra SC/Tyenne SC, Enbrel, Humira/Simlandi/Hadlima, Xeljanz/tofacitinib/Xeljanz XR/tofacitinib ER, Rinvoq
e. Approved Dosing:
i. IV
a) Dosing is based on body weight. Following the initial administration, abatacept should be given at 2 and 4 weeks after the first infusion, then every 4 weeks thereafter
I. < 60kg: 500mg dose
II. 60 – 100kg: 750mg dose

III. > 100kg: 1,000mg dose

ii. SC

a) Dosing for adult rheumatoid arthritis is 125mg once weekly. SC dosing may be initiated with or without a loading dose.
b) If initiating with an IV loading dose, administer the initial IV infusion then administer 125 mg subcutaneously within 24 hours of the infusion, followed by 125 mg subcutaneously once weekly thereafter

2. The patient must have a diagnosis of moderately to severely active **polyarticular Juvenile Idiopathic Arthritis (pJIA)**
   a. Must be prescribed by or in consultation with a Rheumatologist **AND**
   b. Must be at least 2 years old
   c. Must have a contraindication to, have failed to respond to, or must be intolerant to treatment with a disease-modifying antirheumatic drug (DMARD) (such as methotrexate, leflunomide, sulfasalazine), NSAID, analgesic, or corticosteroid
      i. Patients starting on Orencia concurrently with methotrexate, sulfasalazine, or leflunomide will not be subject to the above requirement
   d. The patient must meet one of the following:
      i. **If self-administered**
         a) Treatment with SC Orencia will require drug failure or serious side effects with **TWO** of the following: Enbrel, Humira/Simlandi/Hadlima, Actemra SC/Tyenne SC, Xeljanz/tofacitinib/Xeljanz XR/tofacitinib ER, Rinvoq/LQ
      ii. **If healthcare provider administered**, treatment with IV Orencia will require drug failure or serious side effects with Simponi Aria
         a) Applies to all lines of business
   e. IV Orencia dosing for children 6 years or older with JIA is:
      i. Dosing is based on body weight. Following the initial administration, abatacept should be given at 2 and 4 weeks after the first infusion, then every 4 weeks thereafter
         - < 75kg: 10mg/kg dose
         - > 75kg: administer based on adult dosing
   f. SC Orencia dosing for children 2 years or older with JIA is:
      i. Subcutaneous dosing for juvenile idiopathic arthritis should be initiated at 50mg to 125mg once weekly (weight range-based dosing) without an intravenous loading dose
3. The patient must have a diagnosis of active **Psoriatic Arthritis**
   a. The patient must be at least 18 years of age for treatment with Orencia IV **OR** at least 2 years of age for treatment with Orencia SC **AND**
   b. Must be prescribed by or in consultation with a Rheumatologist or Dermatologist **AND**
   c. The patient must meet one of the following:
      i. **If healthcare provider administered**, treatment with IV Orencia will require documentation of drug failure or serious side effects to **ONE** of the following: Inflectra/Avsola, Selarsdi/Yesintek, Simponi Aria, Tremfya
         a) Applies to all lines of business
         b) IV Orencia dosing is based on body weight. Following the initial administration, abatacept should be given at 2 and 4 weeks after the first infusion, then every 4 weeks thereafter.
            - < 60kg: 500 mg dose
            - 60 – 100kg: 750 mg dose
            - > 100kg: 1,000 mg dose
      ii. **If self-administered**
         a) Treatment with SC Orencia will require documentation of drug failure or serious side effects of **TWO** of the following: Enbrel, Humira/Simlandi/Hadlima, Selarsdi/Yesintek

SC, Xeljanz/tofacitinib/Xeljanz XR/tofacitinib ER, Cosentyx, Otezla/XR, Tremfya, Rinvoq/LQ, Skyrizi

b) Approved dosing for psoriatic arthritis
   I. For adult patients - 125 mg once weekly with or without an IV loading dose
   II. For pediatric patients - 50 mg to 125 mg once weekly (weight range-based dosing) without an intravenous loading dose

4. The patient must have a diagnosis of **acute Graft versus Host Disease (aGvHD)**
   a. The patient must be at least 2 years of age **AND**
   b. Must be used for the prophylaxis of acute GvHD **AND**
   c. Must be undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor **AND**
   d. Must be used in combination with a calcineurin inhibitor and methotrexate
   e. Approved Dose:
      i. For patients 6 years of age and older: 10 mg/kg IV the day before transplantation and on days 5,14, and 28 after transplantation
      ii. For patients 2 years of age to < 6 years of age: 12 mg/kg IV the day before transplantation and on days 5,14, and 28 after transplantation
   f. SC Orencia is NOT FDA approved for the treatment of aGvHD
5. Do not co-administer abatacept with TNF antagonists or any other biologic therapy
6. Quantity limit for subcutaneous (SC) administration:
   a. 125 mg syringe: 4 mL per 28 days (4 syringes)
   b. 87.5 mg syringe: 2.8 mL per 28 days (4 syringes)
   c. 50 mg syringe: 1.6 mL per 28 days (4 syringes)

HCPCS: J0129

Otezla and Otezla XR- apremilast and apremilast ER (Rx)

1. For the treatment of **Plaque Psoriasis**, the patient must meet **(A + B)**
   A. The patient must meet for **ONE** of the following diagnoses (**a or b**)
      a. Must have a diagnosis of ***moderate to severe*** chronic **Plaque Psoriasis** that involves at least 10% of their body surface area. Consideration will be given to those who have less than 10% body surface area involvement but have severe disease of sensitive areas or areas causing significant disruption in normal activities (such as the hands, feet, face, genitalia) **AND**
         i. The patient must be at least 6 years of age **AND**
         ii. Must be prescribed by or in consultation with a Dermatologist or Rheumatologist **OR**
      b. Must have a diagnosis of ***mild*** **Plaque Psoriasis** that involves less than 10% of the body surface area without severe disease of the hands or feet or other areas causing disruption in normal activities **AND**
         i. The patient must be at least 18 years of age **AND**
   B. The patient must be a candidate for systemic therapy or phototherapy and meet for **ONE** of the following (**a or b**)
      a. The patient must have had a 3-month trial of systemic therapy (i.e., acitretin, methotrexate, or cyclosporine) that resulted in an inadequate response (failure). A 3-month trial will not be required if the member experienced serious side effects during a trial of one of the aforementioned agents **OR**
      b. The patient must have had a 3-month trial of Ultraviolet B (UVB) Phototherapy or Psoralen Ultraviolet A (PUVA) Phototherapy that resulted in an inadequate response (failure)
   C. Approved dosing: Initial titration over 5 days followed by the maintenance dosing below:
      i. Age ≥ 6 years of age with weight ≥ 20 to <50 kg: 20 mg orally twice daily.
      ii. Age ≥ 6 years of age with weight ≥ 50 kg: 30 mg orally twice daily **OR** Otezla XR 75mg once daily.
      iii. Adult ≥ 18 years of age: 30 mg orally twice daily **OR** Otezla XR 75mg once daily

2. For the treatment of **Psoriatic Arthritis**
   a. Must be prescribed by or in consultation with a Dermatologist or Rheumatologist
   b. The patient must be at least 6 years of age **AND**
   c. Must have a diagnosis of definitive Psoriatic Arthritis **AND**
   d. Approved dosing: Initial titration over 5 days followed by the maintenance dosing below:
      i. Age ≥ 6 years of age with weight ≥ 20 to <50 kg: 20 mg orally twice daily.
      ii. Age ≥ 6 years of age with weight ≥ 50 kg: 30 mg orally twice daily **OR** Otezla XR 75mg once daily
      iii. Adult ≥ 18 years of age: 30 mg orally twice daily **OR** Otezla XR 75mg once daily
3. For the treatment of **Behcet's Disease**
   a. The patient must have a diagnosis of **oral ulcers associated with Behcet's Disease**
   b. Patient must be at least 18 years of age **AND**
   c. Approved dosing: Initial titration over 5 days followed by the maintenance dosing below:
      i. 30 mg orally twice daily **OR** Otezla XR 75mg once daily
4. Coverage or Otezla/Otezla XR will be limited to Otezla 60 tablets/30 days **OR** Otezla XR 75mg 30 tablets/ 30days
5. Otezla or Otezla XR in combination with biologic DMARD therapy (such as Humira/Simlandi/Hadlima, Enbrel, Cosentyx, etc.) is not FDA approved or supported with a high level of clinically valid medical evidence for the treatment of plaque psoriasis or psoriatic arthritis. Therefore, these requests are considered combination therapy and are considered not medically necessary.

Rhapsido (remibrutinib)-Rx

1. Must be requested by or in consultation with an allergist/immunologist or dermatologist **AND**
2. Patients must be at least 18 years old with the diagnosis of chronic spontaneous urticaria (CSU) defined as at least a 6-week history of urticaria characterized by the development of wheals (hives), angioedema, or both, despite adequate trials (minimum of four weeks each) of:
   a. A second generation H1-antihistamine at standard dosing **AND** a second-generation H1-antihistamine trialed at 2-4 times the standard dose
   b. These criteria may be satisfied by using either the same second generation H1-antihistamine at standard dosing and 2-4 times standard dosing OR using two different second generation H1-antihistamines with at least one agent being at 2-4 times standard dosing
3. Approved Dosing: Rhapsido 25 mg tablet twice daily
4. Initial approval is for 6 months
   a. All recertifications will be for 2 years and will require documentation that the patient has responded to or continues to benefit from therapy (i.e., decreased severity of itching, or size/number of hives).
5. Rhapsido will not be approved for use in combination with Dupixent and Xolair for Chronic Spontaneous Urticaria

Rinvoq/LQ – upadacitinib (Rx)

1. The patient must have a diagnosis of moderately to severely active **Rheumatoid Arthritis**
   a. Must be prescribed by or in consultation with a Rheumatologist **AND**
   b. The patient must be at least 18 years of age **AND**
   c. Must have failed to respond to and/or is intolerant to approved disease-modifying antirheumatic drug (DMARD) agents, such as methotrexate, azathioprine, sulfasalazine, or hydroxychloroquine, either alone or in combination for a 3-month period **AND**
   d. The patient must have had serious side effects or drug failure of Humira/Simlandi/Hadlima or Enbrel for anti-tumor necrosis factor (TNF) naïve patients or with any anti-TNF for anti-TNF experienced patients
   e. Approved dosing is 15 mg once daily

2. The patient must have a diagnosis of active **Psoriatic Arthritis**
   a. Must be prescribed by or in consultation with a Rheumatologist or Dermatologist **AND**
   b. The patient must be at least 2 years of age **AND**
   c. The patient must have had serious side effects or drug failure of Humira/Simlandi/Hadlima or Enbrel for anti-tumor necrosis factor (TNF) naïve patients or with any anti-TNF for anti-TNF experienced patients
   d. Approved dosing is 15 mg once daily
3. The patient must have a diagnosis of **moderate to severe Atopic Dermatitis**
   a. Must be prescribed by or in consultation with an Allergist, Immunologist, Or Dermatologist **AND**
   b. The patient must be at least 12 years of age **AND**
   c. The patient must have a diagnosis of moderate to severe Atopic Dermatitis
      i. Must involve at least 10% body surface area
         a) Consideration will be given to those who have less than 10% body surface area involvement but have severe disease of the hands, feet, or other sensitive areas **OR** severe itch that has been unresponsive to topical therapies
      ii. Must have evidence of functional impact on everyday activities **AND**
   d. Must have had a trial and failure or contraindication to:
      i. Medium to higher potency prescription topical corticosteroid therapy
         a) Adequate trial is defined as ≥ 28 days or for the maximum duration recommended by the product prescribing information (i.e., 14 days for super-potent topical corticosteroids), whichever is shorter **AND**
      ii. Tacrolimus or pimecrolimus
         a) Adequate trial is defined as ≥ 6 weeks based on prescribing information **AND**
      iii. Treatment with at least one of the above therapies must have occurred within the previous 6 months **AND**
   e. Must have had serious side effects or drug failure of systemic therapy that is FDA approved to treat moderate to severe Atopic Dermatitis
   f. Approved dosing:
      i. Pediatric Patients 12 years of age or older weighing at least 40 kg **AND** Adults less than 65 years of age
         a) 15 mg once daily
            I. If an adequate response is not achieved, consider increasing the dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with the 30 mg dose. Use the lowest effective dose needed to maintain response
      ii. Adults 65 years of age or older
         a) 15 mg once daily
   g. Rinvoq will not be approved in combination with Opzelura, Cibinqo, Dupixent, or Adbry
   h. Initial and subsequent approval duration is 2 years
4. The patient must have a diagnosis of moderately to severely active **Crohn's Disease**
   a. Must be prescribed by or in consultation with a Gastroenterologist **AND**
   b. The patient must be at least 18 years of age **AND**
   c. There must be documentation that azathioprine, 6-mercaptopurine, or methotrexate is not effective, contraindicated, or not tolerated **AND**
   d. Must have tried and failed or has documented intolerance to at least ONE of the FDA approved systemic therapies for CD
   e. Approved dosing:
      i. Induction: 45 mg once daily for 12 weeks
      ii. Maintenance: 15 mg once daily
         a) A dose of 30 mg once daily may be considered for patients with refractory, severe, or extensive disease

5. The patient must have a diagnosis of moderately to severely active **Ulcerative Colitis**
   a. Must be prescribed by or in consultation with a Gastroenterologist **AND**
   b. The patient must be at least 18 years of age **AND**
   c. Must meet for ONE of the following **(A or B):**
      A. Must have tried and failed or has documented intolerance to at least ONE of the FDA approved systemic therapies for UC
      B. The patient has been diagnosed with pouchitis and has tried an antibiotic, corticosteroid enema, or mesalamine enema **AND**
   d. Approved dosing:
      i. Induction: 45 mg once daily for 8 weeks
      ii. Maintenance: 15 mg once daily
         a) A dose of 30 mg once daily may be considered for patients with refractory, severe, or extensive disease
6. The patient must have a diagnosis of **Ankylosing Spondylitis**
   a. The patient must be at least 18 years of age **AND**
   b. Must be prescribed by or in consultation with a Rheumatologist **AND**
   c. Must have refractory disease defined by failure of or intolerance to at least TWO different NSAIDS at maximum strength for at least 1 month each **AND**
   d. The patient must have had serious side effects or drug failure of Humira/Simlandi/Hadlima or Enbrel for anti-tumor necrosis factor (TNF) naïve patients or with any anti-TNF for anti-TNF experienced patients
   e. Approved dosing is 15 mg once daily
7. The patient must have a diagnosis of **Non-Radiographic Axial Spondylitis (nr-axSpA)**
   a. The patient must be at least 18 years of age **AND**
   b. Must be prescribed by or in consultation with a Rheumatologist **AND**
   c. Must have refractory disease defined by failure of or intolerance to at least **TWO** different NSAIDS at maximum strength for at least 1 month each **AND**
   d. The patient must have documentation of serious side effects or drug failure of Cimzia
   e. Approved dosing is 15 mg once daily
8. The patient must have a diagnosis of moderately to severely active **polyarticular Juvenile Idiopathic Arthritis (pJIA)**
   a. Must be prescribed by or in consultation with a Rheumatologist **AND**
   b. The patient must be at least 2 years old **AND**
   c. Must have a contraindication to have failed to respond to, or must be intolerant to treatment with a disease-modifying antirheumatic drug (DMARD) (such as methotrexate, leflunomide, sulfasalazine), NSAID, analgesic, or corticosteroid
      i. Patients starting on Rinvoq/LQ concurrently with methotrexate, sulfasalazine, or leflunomide will not be subject to the above requirement
   d. The patient must have had serious side effects or drug failure of Humira/Simlandi/Hadlima or Enbrel for anti-tumor necrosis factor (TNF) naïve patients or with any anti-TNF for anti-TNF experienced patients
9. The patient must have a diagnosis of Giant Cell Arteritis
   a. Must be at least 18 years of age
   b. Must be prescribed by or in consultation with an Ophthalmologist, Neurologist, or Rheumatologist
   c. Approved dosing: Rinvoq 15mg once daily in combination with a tapering course of corticosteroid, or as a monotherapy following discontinuation of corticosteroids
10. Rinvoq is available as 15 mg, 30 mg, 45 mg tablets and the quantity will be limited to 30 tablets per 30 days for each strength

a. Rinvoq 45 mg will be over for a max of 84 tablets/365 days to allow for the induction dosing applicable to Crohn's Disease (12 weeks) and Ulcerative Colitis (8 weeks)

11. Rinvoq LQ is a new formulation of Rinvoq and is only approved for PsA and pJIA

Siliq – brodalumab (Rx)

1. Must be prescribed by or in consultation with a Dermatologist or Rheumatologist **AND**
2. The patient must be at least 18 years of age **AND**
3. Must have moderate to severe chronic **plaque psoriasis** that involves at least 10% of the body surface area. Consideration will be given to those who have less than 10% body surface area involvement but have severe disease of sensitive areas or areas causing significant disruption in normal activities (such as the hands, feet, face, genitalia) **AND**
4. The patient must be a candidate for systemic therapy or phototherapy and meet for **ONE** of the following (**A or B**)
   - **A.** The patient must have had a 3-month trial of systemic therapy (i.e., acitretin, methotrexate, or cyclosporine) that resulted in an inadequate response (failure). A 3-month trial will not be required if the member experienced serious side effects during a trial of one of the aforementioned agents **OR**
   - **B.** The patient must have had a 3-month trial of Ultraviolet B (UVB) Phototherapy or Psoralen Ultraviolet A (PUVA) Phototherapy that resulted in an inadequate response (failure)
5. The patient must also have a documented drug failure or serious side effects to **ALL** the following: Humira/Simlandi/Hadlima, Otezla/XR, Selarsdi/Yesintek, Skyrizi, Tremfya, Enbrel, Cosentyx, Cimzia, Taltz, Sotyktu, and Bimzelx
6. Siliq is contraindicated in patients with Crohn's Disease
7. Coverage of Siliq will be limited to an initial induction dose of 210 mg subcutaneous injection at weeks 0, 1, and 2 followed by 210 mg every 2 weeks

Skyrizi IV & SC – risankizumab-rzaa IV (Medical), risankizumab-rzaa SC (Rx)

1. The patient must have moderate to severe chronic **Plaque Psoriasis** that involves at least 10% of the body surface area. Consideration will be given to those who have less than 10% body surface area involvement but have severe disease of sensitive areas or areas causing significant disruption in normal activities (such as the hands, feet, face, genitalia) **AND**
   a. Must be prescribed by or in consultation with a Dermatologist or Rheumatologist **AND**
   b. The patient must be at least 6 years of age **AND**
   c. The patient must be a candidate for systemic therapy or phototherapy and meet for **ONE** of the following (**A or B**)
      - **A.** The patient must have had a 3-month trial of systemic therapy (i.e., acitretin, methotrexate, or cyclosporine) that resulted in an inadequate response (failure). A 3-month trial will not be required if the member experienced serious side effects during a trial of one of the aforementioned agents **OR**
      - **B.** The patient must have had a 3-month trial of Ultraviolet B (UVB) Phototherapy or Psoralen Ultraviolet A (PUVA) Phototherapy that resulted in an inadequate response (failure)
2. The patient must have a diagnosis of active **Psoriatic Arthritis AND**
   a. The patient must be at least 6 years of age **AND**
   b. Must be prescribed by or in consultation with a Dermatologist or Rheumatologist **OR**
3. The patient must have a diagnosis of moderately to severely active **Crohn's Disease**
   a. The patient must be at least 18 years of age **AND**
   b. Must be prescribed by or in consultation with a Gastroenterologist **AND**
   c. There must be documentation that azathioprine, 6-mercaptopurine, or methotrexate is not effective, contraindicated, or not tolerated
   d. Treatment with a biologic medication as first-line therapy will be assessed on a case-by-case basis through a letter of medical necessity and clinical progress notes based on severity of the

disease (such as but not limited to enterocutaneous [perianal or abdominal] fistulas, rectovaginal fistulas, ileocolonic resection)

4. The patient must have a diagnosis of moderately to severely active **Ulcerative Colitis**
   a. Must be prescribed by or in consultation with a Gastroenterologist
   b. Must be at least 18 years old
   c. Must meet for ONE of the following **(A or B):**
      A. Must have tried and failed or has documented intolerance to at least **ONE** of the following conventional therapies for at least 3 months:
         i. Thiopurines: Azathioprine/6-mercaptopurine (6-MP)
         ii. 5-Aminosalicylates: Sulfasalazine, Mesalamine, Olsalazine
         iii. IV or oral steroids - note, a 3-month trial of systemic steroid therapy will not be required
      B. The patient has been diagnosed with pouchitis and has tried an antibiotic, corticosteroid enema, or mesalamine enema
5. Approved Dose: *Skyrizi **IV** requires prior authorization for new starts only.*
   a. For **Psoriatic Arthritis** and **Plaque Psoriasis**:
      i. Adults: 150 mg at weeks 0, 4, and then every 12 weeks thereafter
      ii. Pediatric Patients 6 years and older:
         - Patients weighing less than 40kg:
            - 55 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter
         - Patients weighing 40kg or greater:
            - 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.
   b. For **Crohn's Disease**: 600 mg given by intravenous (IV) infusion at weeks 0, 4, and 8, followed by 180 mg or 360 mg administered subcutaneously at week 12, and every 8 weeks thereafter
   c. For **Ulcerative Colitis**: induction therapy of 1200 mg given by intravenous (IV) infusion at weeks 0, 4 and 8, followed by maintenance therapy of 180 mg or 360 mg administered subcutaneously every 8 weeks thereafter
6. Skyrizi is available as a:
   a. 55 mg/0.37mL single-dose prefilled syringe
   b. 150 mg/mL single-dose prefilled pen
   c. 150 mg/mL single-dose prefilled syringe
   d. 180mg/1.2mL (150mg/mL) single-dose prefilled syringe
   e. 180 mg/1.2 mL (150mg/mL) single-dose prefilled cartridge with on-body injector
   f. 360 mg/2.4 mL (150mg/mL) single-dose prefilled cartridge with on-body injector
   g. 600 mg/10 mL single-dose vial for intravenous infusion
7. Quantity limit
   a. For Psoriatic Arthritis and Plaque Psoriasis:
      i. Coverage of the initial loading dose will be limited to 2 kits/pens/syringes for the first month of therapy and is covered under the pharmacy benefit
      ii. Coverage of ongoing maintenance therapy will be limited to 1 kit/pen/syringe per 84 days
   b. For Crohn's Disease and Ulcerative Colitis:
      i. The initial loading dose will be covered under the medical benefit (if applicable)
      ii. Coverage of ongoing maintenance therapy will be limited to 1 prefilled cartridge with on-body injector per 56 days

HCPCS: J2327

Simponi/Simponi Aria - golimumab (Medical or Rx)

1. The patient must have a diagnosis of moderately to severely active **Rheumatoid Arthritis**
   a. The patient must be at least 18 years of age **AND**

b. Must be prescribed by or in consultation with a Rheumatologist **AND**
c. Must have failed to respond to and/or is intolerant to approved disease-modifying antirheumatic drug (DMARD) agents, such as methotrexate, azathioprine, sulfasalazine, or hydroxychloroquine, either alone or in combination for a 3-month period **AND**
d. Simponi/Simponi Aria must be used in combination with methotrexate. Consideration for the use without concurrent methotrexate may be given to patients who have a previous intolerance or contraindication to methotrexate therapy **AND**
e. Treatment with SC Simponi (self-administered) will require documentation of drug failure or serious side effects of **TWO** of the following: Actemra SC/Tyenne SC, Enbrel, Humira/Simlandi/Hadlima, Xeljanz/tofacitinib/Xeljanz XR/tofacitinib ER, Rinvoq
f. Simponi Aria dosing for adults with RA is as follows:
   i. Dosing is 2mg/kg IV infusion at week 0 and 4 and then every 8 weeks thereafter
g. SC Simponi dosing for adults with RA is as follows:
   i. 50mg once monthly

2. The patient must have a diagnosis of active **Psoriatic Arthritis**
   a. Must be prescribed by or in consultation with a Dermatologist or Rheumatologist **AND**
   b. The patient must be 2 years of age or older
   c. Treatment with SC Simponi (self-administered) will require documentation of drug failure or serious side effects of **TWO** of the following: Enbrel, Humira/Simlandi/Hadlima, Selarsdi/Yesintek SC, Xeljanz/tofacitinib/Xeljanz XR/tofacitinib ER, Cosentyx, Otezla/XR, Tremfya, Rinvoq, Skyrizi
   d. Simponi Aria dosing for patients with PsA is as follows:
      i. Adult patients: 2 mg/kg IV at weeks 0, 4, and then every 8 weeks thereafter
      ii. Pediatric patients: 80 mg/m^2 at weeks 0, 4, and then every 8 weeks thereafter
   e. SC Simponi dosing for adult patients with PsA is as follows:
      i. 50mg once monthly
   f. SC Simponi is not FDA approved to treat PsA in pediatric patients
3. The patient must have a diagnosis of **Ankylosing Spondylitis**
   a. The patient must be at least 18 years of age **AND**
   b. Must be prescribed by or in consultation with a Rheumatologist **AND**
   c. Must have refractory disease defined by failure of or intolerance to at least **TWO** different NSAIDS at maximum strength for at least 1 month each
   d. Treatment with SC Simponi (self-administered) will require documentation of drug failure or serious side effects of **TWO** of the following: Enbrel, Humira/Simlandi/Hadlima, Cosentyx, Xeljanz/tofacitinib/Xeljanz XR/tofacitinib ER, Rinvoq
   e. Simponi Aria dosing for adults with AS is as follows:
      i. 2 mg/kg IV at weeks 0, 4, and then every 8 weeks thereafter
   f. SC Simponi dosing for adults with AS is as follows:
      i. 50mg once monthly
4. The patient must have a diagnosis of moderately to severely active **Ulcerative Colitis**
   a. Must be adult or pediatric patient weighing at least 15kg **AND**
   b. Must be prescribed by or in consultation with a Gastroenterologist **AND**
   c. Must meet for ONE of the following **(A or B):**
      A. Must have tried and failed or has documented intolerance to at least ONE of the following conventional therapies for at least 3 months
         I. Thiopurines: azathioprine/6-mercaptopurine (6-MP)
         II. 5-Aminosalicylates: sulfasalazine, mesalamine, olsalazine
         III. IV or oral steroids - note, a 3-month trial of systemic steroid therapy will not be required
      B. The patient has been diagnosed with pouchitis and has tried an antibiotic, corticosteroid enema, or mesalamine enema

d. Treatment with SC Simponi (self-administered) will require drug failure or serious side effects with Humira/Simlandi/Hadlima
e. SC Simponi dosing for adults and pediatric patients with UC is as follows:

Weight for Patients with UC	Week 0	Week 2	Week 6 and every 4 weeks thereafter
Adults and pediatric patients 40kg and greater	200mg	100mg	100mg
Pediatric patients at least 15 kg to less than 40kg	100mg	50mg	50mg

f. Simponi Aria is not FDA approved for the treatment of Ulcerative Colitis

5. A diagnosis of **irritable bowel disease associated arthritis** will be evaluated using criteria for ankylosing spondylitis
6. The patient must have a diagnosis of moderately to severely active **polyarticular Juvenile Idiopathic Arthritis (pJIA)**
   a. Must be prescribed by or in consultation with a Rheumatologist **AND**
   b. The patient must be at least 2 years old **AND**
   c. Must have a contraindication to, have failed to respond to, or must be intolerant to treatment with a disease-modifying antirheumatic drug (DMARD) (such as methotrexate, leflunomide, sulfasalazine), NSAID, analgesic, or corticosteroid
      i. Patients starting on Simponi/Simponi Aria concurrently with methotrexate, sulfasalazine, or leflunomide will not be subject to the above requirement
   d. Simponi Aria dosing for pediatric patients with pJIA is 80 mg/m2 IV at weeks 0 and 4 followed by 80 mg/m2 IV every 8 weeks thereafter
   e. SC Simponi is not FDA approved for the treatment of pJIA
7. Simponi Aria is intended for coverage under the medical benefit (healthcare provider administered)
8. Simoni SC is intended for coverage under the pharmacy benefit (self-administered)
9. Quantity Limit under the pharmacy benefit:
   a. Simponi 50 mg: 0.5 mL per 30 days
   b. Simponi 100 mg: 1 mL per 30 days

HCPCS: J1602

Sotyktu – deucravacitinib (Rx)

1. The patient must be at least 18 years of age **AND**
2. Must be prescribed by or in consultation with a Dermatologist or Rheumatologist **AND (I OR II)**
   I. The patient must have moderate to severe chronic **plaque psoriasis** that involves at least 10% of the body surface area. Consideration will be given to those who have less than 10% body surface area involvement but have severe disease of sensitive areas or areas causing significant disruption in normal activities (such as the hands, feet, face, genitalia) **AND**
      a) The patient must be a candidate for systemic therapy or phototherapy and meet for **ONE** of the following (**A or B**)
         A. The patient must have had a 3-month trial of systemic therapy (i.e., acitretin, methotrexate, or cyclosporine) that resulted in an inadequate response (failure). A 3-month trial will not be required if the member experienced serious side effects during a trial of one of the aforementioned agents **OR**
         B. The patient must have had a 3-month trial of Ultraviolet B (UVB) Phototherapy or Psoralen Ultraviolet A (PUVA) Phototherapy that resulted in an inadequate response (failure)
   II. The patient must have a diagnosis of **active Psoriatic Arthritis AND**
3. There must be documentation of drug failure or serious side effects to **ONE** of the following: Humira/Simlandi/Hadlima, Otezla/XR, Selarsdi/Yesintek, Skyrizi, Tremfya, Cosentyx, Enbrel
4. Approved Dosing: 6 mg by mouth once daily

Quantity Limit: 30 tablets/30 days

Spevigo – spesolimab-sbzo (Medical or Rx)

1. The patient must be at least 12 years of age and weigh at least 40 kilograms (kg) **AND**
2. Must be prescribed by or in consultation with a dermatologist or a physician specializing in the treatment of autoinflammatory conditions **AND**
3. The patient must have a confirmed diagnosis of generalized pustular psoriasis (GPP) defined as the presence of primary, sterile, macroscopically visible pustules on non-acral skin (excluding cases where pustulation is restricted to psoriatic plaques) **AND**
4. Must meet ONE of the following **(A or B):**
   - **A.** Request for Spevigo intravenous (IV) injection:
     - I. Must be used for the treatment of a generalized pustular psoriasis (GPP) moderate to severe *flare* in patients with a history of at least 2 moderate to severe GPP flares defined as:
       - a. A Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score of ≥ 3 **AND**
       - b. New appearance or worsening of existing pustules **AND**
       - c. A GPPGA pustulation sub score of ≥ 2 **AND**
       - d. ≥ 5% body surface covered with erythema and the presence of pustules
     - II. Requests for **an additional dose** used to treat the **same flare** will be covered if the patient meets the following criteria:
       - a. The additional dose will be used no sooner than 1 week after the initial dose **AND**
       - b. The patient has a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score of 2 or higher at the end of week 1 (range, 0 [clear skin] to 4 [severe disease]) **AND**
       - c. The patient has a GPPGA pustulation sub score of 2 or higher at the end of week 1 (range, 0 [no visible pustules] to 4 [severe pustulation])
   - **B.** Request for Spevigo subcutaneous (SC) injection: Must be used for the treatment of generalized pustular psoriasis (GPP) as ongoing treatment when NOT experiencing a flare **AND**
     - a. The patient must have a history of at least 1 moderate to severe GPP flares (as defined above)
5. Requests for **Recertification**
   - a. Individuals that have previously received at least 1 dose of Spevigo for the treatment of a prior GPP flare will be covered for a **recurrent flare** if the patient achieved a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score of 0 or 1 after previous treatment **AND** had an increase of at least 2 points in both GPPGA total score and pustulation subscore after previous treatment
   - b. Ongoing maintenance treatment recertification will require attestation of disease improvement such as a decrease in the number of flares per year or a decrease in the severity of symptoms experiences during flares.
6. Medical and Pharmacy Benefit Coverage
   - a. Spevigo IV
     - i. Covered under the Medical Benefit for the treatment of GPP flares
     - ii. Spevigo IV will not be covered for the ongoing treatment of GPP (as a one-time loading dose or as maintenance treatment)
   - b. Spevigo SC
     - i. For Commercial/Exchange/Essential Plan/Child Health Plus, Spevigo SC will be covered under the Pharmacy Benefit for the *treatment of GPP when not experiencing a flare of GPP* as ongoing and maintenance therapy
     - ii. For all lines of business except Medicare Advantage, Spevigo SC as ongoing and maintenance treatment of GPP when not experiencing a flare will **not** be covered under the

Medical Benefit unless the patient has an inability to self-inject. For pediatric patients less than 18 years of age, documentation must also include the inability of a caregiver to administer the medication.
   iii. Spevigo SC 600 mg one-time loading dose for the treatment of GPP when not experiencing a flare is covered under the Medical Benefit
   iv. Spevigo SC will not be covered for the treatment of GPP flares
7. Approval Timeframe:
   a. Treatment of a flare with intravenous (IV) Spevigo: 1 week per request (new, additional, and recertification)
   b. One-time Loading Dose: 1 month
   c. Ongoing subcutaneous (SC) Treatment
      i. New Starts: 6 months
      ii. Recertification: 1 year
8. Approved Dosing:
   a. Experiencing a flare: 900 mg dose by intravenous (IV) infusion over 90 minutes
      i. If GPP flare symptoms persist, an additional intravenous (IV) 900 mg dose (over 90 minutes) may be administered one week after the initial dose (the criteria listed in 6 must be met for coverage for an additional dose)
   b. Initiating ongoing treatment
      i. <u>After experiencing a flare treated with Spevigo</u>: 300 mg administered subcutaneously (SC) 4 weeks after treatment of the flare and every 4 weeks thereafter
      ii. <u>Without experiencing a flare</u>: a one-time 600 mg loading dose administered subcutaneously (SC) followed by 300 mg maintenance dose 4 weeks later and every 4 weeks thereafter
      iii. The one-time 600 mg SC loading dose will **NOT** be covered for patients initiating ongoing treatment within 4 weeks of receiving Spevigo 900 mg for treatment of a GPP flare
   c. Reinitiating ongoing treatment after experiencing a flare treated with Spevigo: 300 mg administered subcutaneously (SC) 4 weeks after treatment of the flare and every 4 weeks thereafter
9. Coverage will not be granted for any non-Food and Drug Administration indications (such as acute generalized exanthematous pustulosis [AGEP], acrodermatitis continua of Hallopeau [ACH], palmoplantar pustulosis [PPP], chronic plaque psoriasis, guttate psoriasis, and erythrodermic psoriasis)
10. Spevigo will not be covered for patients currently on biologic therapy
11. Patients currently treated with Spevigo as ongoing SC maintenance treatment will require prior authorization of Spevigo IV for the treatment of NEW flares and must satisfy the criteria above
12. Quantity Limit
    a. Pharmacy Benefit: 2 mL/28 days
13. Coverage of an additional quantity will not be granted

<u>HCPCS</u>: J1747

Taltz – ixekizumab (Rx)

1. The patient must have a diagnosis of **Ankylosing Spondylitis**
   a. Must be prescribed by or in consultation with a Rheumatologist
   b. The patient must be at least 18 years of age
   c. Must have refractory disease defined by failure of or intolerance to at least **TWO** different NSAIDS at maximum strength for at least 1 month each **AND**
   d. There must be documentation of drug failure or serious side effects to **TWO** of the following: Enbrel, Humira/Simlandi/Hadlima, Cosentyx, Xeljanz/tofacitinib/Xeljanz XR/tofacitinib ER, Rinvoq
2. The patient must have moderate to severe chronic **Plaque Psoriasis** that involves at least 10% of the body surface area. Consideration will be given to those who have less than 10% body surface

area involvement but have severe disease of sensitive areas or areas causing significant disruption in normal activities (such as the hands, feet, face, genitalia) **AND**
   a. Must be prescribed by or in consultation with a Dermatologist or Rheumatologist
   b. The patient must be at least 6 years of age
      I. The patient must be a candidate for systemic therapy or phototherapy and meet for **ONE** of the following (**A or B**)
         A. The patient must have had a 3-month trial of systemic therapy (i.e., acitretin, methotrexate, or cyclosporine) that resulted in an inadequate response (failure). A 3-month trial will not be required if the member experienced serious side effects during a trial of one of the aforementioned agents **OR**
         B. The patient must have had a 3-month trial of Ultraviolet B (UVB) Phototherapy or Psoralen Ultraviolet A (PUVA) Phototherapy that resulted in an inadequate response (failure)
   c. The patient must also have a documented drug failure or serious side effects to **TWO** of the following: Humira/Simlandi/Hadlima, Otezla/XR, Sotyktu, Selarsdi/Yesintek SC, Skyrizi, Tremfya, Cosentyx, Enbrel
3. Must have a diagnosis of active **Psoriatic Arthritis**
   a. The patient must be at least 18 years old **AND**
   b. Must be prescribed by or in consultation with a Rheumatologist or Dermatologist **AND**
   c. The patient must also have a documentation drug failure or serious side effects with **TWO** of the following: Enbrel, Humira/Simlandi/Hadlima, Selarsdi/Yesintek SC, Xeljanz/tofacitinib/Xeljanz XR/tofacitinib ER, Cosentyx, Otezla/XR, Tremfya, Skyrizi, Rinvoq
4. Must have a diagnosis of **Non-Radiographic Axial Spondylitis (nr-axSpA)**
   a. The patient must be at least 18 years of age **AND**
   b. Must be prescribed by or in consultation with a Rheumatologist **AND**
   c. Must have refractory disease defined by failure of or intolerance to at least **TWO** different NSAIDS at maximum strength for at least 1 month each **AND**
   d. The patient must also have a documentation drug failure or serious side effects with **TWO** of the following: Rinvoq, Cimzia, Cosentyx
5. Individuals are excluded from coverage if they have an active TB infection
6. Coverage of Taltz will be limited to:
   a. an initial induction dose of 160mg subcutaneous injection at week 0, then 80mg SC weeks 2,4,6,8,10 and 12 and then maintenance dosing of 80mg every 4 weeks for <u>adults</u> with **Plaque Psoriasis** and **Psoriatic arthritis with comorbid Plaque Psoriasis**
      i. For <u>pediatric</u> patients 6 years or older with **Plaque Psoriasis**:
         a) Body weight less than 25kg: 40 mg SC at week 0, followed by 20 mg every 4 weeks thereafter
         b) Body weight 25 kg to 50 kg: 80 mg SC at week 0, followed by 40 mg every 4 weeks thereafter
         c) Body weight greater than 50 kg: 160 mg SC at week 0, followed by 80 mg every 4 weeks thereafter
   b. An initial induction dose of 160mg subcutaneous injection at week 0, followed by a maintenance dose of 80mg every 4 weeks for **Ankylosing Spondylitis** and **Psoriatic Arthritis**
   c. 80mg subcutaneously every 4 weeks for **Non-Radiographic Axial Spondyloarthritis**

Tremfya – guselkumab (Medical or Rx)

1. The patient must have moderate to severe chronic **Plaque Psoriasis** that involves at least 10% of the body surface area. Consideration will be given to those who have less than 10% body surface area involvement but have severe disease of sensitive areas or areas causing significant disruption in normal activities (such as the hands, feet, face, genitalia) **AND**
   a. Must be prescribed by or in consultation with a Dermatologist or Rheumatologist **AND**
   b. The patient must be at least 6 years of age who also weighs at least 40kg **AND**

c. The patient must be a candidate for systemic therapy or phototherapy and meet for **ONE** of the following (**A or B**)
   A. The patient must have had a 3-month trial of systemic therapy (i.e., acitretin, methotrexate, or cyclosporine) that resulted in an inadequate response (failure). A 3-month trial will not be required if the member experienced serious side effects during a trial of one of the aforementioned agents **OR**
   B. The patient must have had a 3-month trial of Ultraviolet B (UVB) Phototherapy or Psoralen Ultraviolet A (PUVA) Phototherapy that resulted in an inadequate response (failure)

2. The patient must have a diagnosis of active **Psoriatic Arthritis AND**
   a. The patient must be at least 6 years of age who also weighs at least 40kg **AND**
   b. Must be prescribed by or in consultation with a Rheumatologist or Dermatologist
3. Coverage of Tremfya for **Plaque Psoriasis** and **Psoriatic Arthritis** will be limited to an initial induction dose of 100 mg subcutaneous injection at weeks 0 and 4, and then maintenance dosing of 100mg every 8 weeks thereafter
4. The patient must have a diagnosis of moderately to severely active **Ulcerative Colitis**
   a. Must be prescribed by or in consultation with a Gastroenterologist
   b. Must be at least 18 years old
   c. Must meet for ONE of the following **(A or B):**
      A. Must have tried and failed or has documented intolerance to at least **ONE** of the following conventional therapies for at least 3 months:
         I. Thiopurines: Azathioprine/6-mercaptopurine (6-MP)
         II. 5-Aminosalicylates: Sulfasalazine, Mesalamine, Olsalazine
         III. IV or oral steroids - note, a 3-month trial of systemic steroid therapy will not be required
      B. The patient has been diagnosed with pouchitis and has tried an antibiotic, corticosteroid enema, or mesalamine enema
   d. Coverage of Tremfya for **Ulcerative Colitis** will be limited to the following:
      i. **Induction**: **(A or B)**
      A. 200 mg administered by intravenous infusion at Week 0, 4 and 8.
         I. Approval is for 3 induction doses in 12 weeks as medical benefit. **OR**
      B. 400 mg (Induction Pack for UC or CD: 2 x 200mg/2mL single-dose prefilled pens) administered by subcutaneous injection at Week 0, 4, and 8.
         I. Approval is for 3 induction doses in 12 weeks
      ii. **Maintenance: (A or B)**
      A. 100 mg administered by subcutaneous injection at Week 16, and every 8 weeks thereafter **OR**
      B. 200 mg administered by subcutaneous injection at Week 12, and every 4 weeks thereafter.
      *Use the lowest effective recommended dosage to maintain therapeutic response
5. The patient must have a diagnosis of moderately to severely active **Crohn's Disease**
   a. Must be prescribed by or in consultation with a Gastroenterologist
   b. Must be at least 18 years of age
   c. There must be documentation that azathioprine, 6-mercaptopurine, or methotrexate is not effective, contraindicated, or not tolerated
      i. Treatment with a biologic medication as first-line therapy will be assessed on a case-by-case basis through a letter of medical necessity and clinical progress notes based on severity of the disease (such as but not limited to enterocutaneous [perianal or abdominal] fistulas, rectovaginal fistulas, ileocolonic resection)
   d. Coverage of Tremfya for Crohn's Disease will be limited to the following:
      i. **Induction**: **(A or B)**
      A. 200 mg administered by intravenous infusion at Week 0, 4 and 8.
         I. Approval is for 3 induction doses in 12 weeks as medical benefit. **OR**

B. 400 mg (Induction Pack for UC or CD: 2 x 200mg/2mL single-dose prefilled pens) administered by subcutaneous injection at Week 0, 4, and 8.
I. Approval is for 3 induction doses in 12 weeks
ii. **Maintenance**: **(A or B)**
A. 100 mg administered by subcutaneous injection at Week 16, and every 8 weeks thereafter **OR**
B. 200 mg administered by subcutaneous injection at Week 12, and every 4 weeks thereafter.
*Use the lowest effective recommended dosage to maintain therapeutic response

6. **Quantity limit**:
   a. 100mg/mL (autoinjector, prefilled syringe) 1mL per 56 days
   b. 200mg/2mL (autoinjector, prefilled syringe) 2mL per 28 days
   c. Induction Pack for UC or CD (2 x 200 mg/2 mL single-dose prefilled pens): 4 mL/365 days
      i. A maximum of 12 mL/56 days will be granted to allow for completion of induction dosing during the first 8 weeks of treatment

HCPCS: J1628

Velsipity – etrasimod (Rx)

1. Must be prescribed by or in consultation with a Gastroenterologist **AND**
2. The patient must be at least 18 years of age **AND**
3. The patient must have a diagnosis of moderately to severely active **Ulcerative Colitis AND**
4. Must meet for **ONE** of the following **(A or B):**
   A. Must have tried and failed or has documented intolerance to at least ONE of the following conventional therapies for at least 3 months:
      I. Thiopurines: Azathioprine/6-mercaptopurine (6-MP)
      II. 5-Aminosalicylates: Sulfasalazine, Mesalamine, Olsalazine
      III. IV or oral steroids - note, a 3-month trial of systemic steroid therapy will not be required
   B. The patient has been diagnosed with pouchitis and has tried an antibiotic, corticosteroid enema, or mesalamine enema **AND**
5. The patient must have had serious side effects or drug failure of **TWO** of the following: Humira/Simlandi/Hadlima, Selarsdi/Yesintek, Skyrizi, Tremfya
6. Approved dosing: 2 mg by mouth once daily
7. Quantity Limit: 30 tablets/30 days

Xeljanz and Xeljanz XR- tofacitinib and tofacitinib ER (Rx)

1. The patient must have a diagnosis of moderately to severely active **Rheumatoid Arthritis**
   a. The patient must be at least 18 years of age **AND**
   b. Must be prescribed by or in consultation with a Rheumatologist **AND**
   c. Must have failed to respond to and/or is intolerant to approved disease-modifying antirheumatic drug (DMARD) agents, such as methotrexate, azathioprine, sulfasalazine, or hydroxychloroquine, either alone or in combination for a 3-month period **AND**
   d. The patient must have had serious side effects or drug failure of Humira/Simlandi/Hadlima or Enbrel for anti-tumor necrosis factor (TNF) naïve patients or with any anti-TNF for anti-TNF experienced patients
2. The patient must have a diagnosis of active **Psoriatic Arthritis**
   a. The patient must be at least 2 years of age **AND**
   b. Must be prescribed by or in consultation with a Rheumatologist or Dermatologist **AND**
   c. The patient must have had serious side effects or drug failure of Humira/Simlandi/Hadlima or Enbrel for anti-tumor necrosis factor (TNF) naïve patients or with any anti-TNF for anti-TNF experienced patients
3. The patient must have a diagnosis of moderately to severely active **Ulcerative Colitis**
   a. The patient must be at least 18 years of age **AND**
   b. Must be prescribed by or in consultation with a Gastroenterologist **AND**

c. Must meet for **ONE** of the following **(A or B):**
   A. Must have tried and failed or has documented intolerance to at least ONE of the following conventional therapies for at least 3 months:
      I. Thiopurines: azathioprine/6-mercaptopurine (6-MP)
      II. 5-Aminosalicylates: sulfasalazine, mesalamine, olsalazine
      III. IV or oral steroids - note, a 3-month trial of systemic steroid therapy will not be required
   B. The patient has been diagnosed with pouchitis and has tried an antibiotic, corticosteroid enema, or mesalamine enema **AND**
d. The patient must have had serious side effects or drug failure of Humira/Simlandi/Hadlima for anti-tumor necrosis factor (TNF) naïve patients or with any anti-TNF for anti-TNF experienced patients

4. The patient must have a diagnosis of moderately to severely active **polyarticular Juvenile Idiopathic Arthritis (pJIA)**
   a. Must be prescribed by or in consultation with a Rheumatologist **AND**
   b. The patient must be at least 2 years old **AND**
   c. Must have a contraindication to, have failed to respond to, or must be intolerant to treatment with a disease-modifying antirheumatic drug (DMARD) (such as methotrexate, leflunomide, sulfasalazine), NSAID, analgesic, or corticosteroid
      i. Patients starting on Xeljanz/tofacitinib/Xeljanz XR/tofacitinib ER concurrently with methotrexate, sulfasalazine, or leflunomide will not be subject to the above requirement
   d. The patient must have had serious side effects or drug failure of Humira/Simlandi/Hadlima or Enbrel for anti-tumor necrosis factor (TNF) naïve patients or with any anti-TNF for anti-TNF experienced patients
   e. The approved dose of Xeljanz/tofacitinib for pJIA is as follows:
      i. 10 to < 20 kg: 3.2 mg oral solution twice daily
      ii. 20 kg to < 40 kg: 4 mg oral solution twice daily
      iii. ≥ 40 kg: 5 mg oral tablet or oral solution twice daily
   f. Xeljanz XR/tofacitinib ER is not FDA approved for the treatment of pJIA
5. The patient must have a diagnosis of **Ankylosing Spondylitis**
   a. The patient must be at least 18 years of age **AND**
   b. Must be prescribed by or in consultation with a Rheumatologist **AND**
   c. Must have refractory disease defined by failure of or intolerance to at least **TWO** different NSAIDS at maximum strength for at least 1 month each **AND**
   d. The patient must have had serious side effects or drug failure of Humira/Simlandi/Hadlima or Enbrel for anti-tumor necrosis factor (TNF) naïve patients or with any anti-TNF for anti-TNF experienced patients
6. Xeljanz/tofacitinib/Xeljanz XR/tofacitinib ER has not been found to be safe and effective for and is not FDA approved for the treatment of alopecia (including but not limited to alopecia areata, alopecia universalis) and will be subject to off label review and policy criteria. In addition, the use of Xeljanz/tofacitinib/Xeljanz XR/tofacitinib ER for the treatment of alopecia is considered a cosmetic use (defined as use to improve a patient's appearance and/or self-esteem). The use of a drug, whether it is for a Food and Drug Administration (FDA) approved or off-label indication, for a cosmetic use is considered not medically necessary.
7. Xeljanz/tofacitinib oral solution is supplied in a 240 mL bottle with a concentration of 1 mg/mL and is only FDA approved for the treatment of pJIA
8. Coverage will be limited to:
   a. 60 tablets/30 days for Xeljanz/tofacitinib
   b. 30 tablets/30 days for Xeljanz XR/tofacitinib ER
   c. 300 mL/30 days for Xeljanz/tofacitinib oral solution

Zymfentra - infliximab-dyyb (Rx)

1. Based on comparable indications, efficacy, safety profile, and affordability of Avsola and Inflectra, the member will be required to use Avsola and Inflectra and as such, the use of Zymfentra for FDA approved indications (Crohn's Disease and Ulcerative Colitis) is considered not medically necessary.
2. For all non-FDA approved indications, the use of Zymfentra is considered not medically necessary

HCPCS: J1748 (effective 7/1/24)

Zeposia- ozanimod (Rx)

1. The patient must have a diagnosis of **Multiple Sclerosis OR**
2. The patient must have a diagnosis of moderately to severely active **Ulcerative Colitis**
   a. The patient must be at least 18 years of age **AND**
   b. Must be prescribed by or in consultation with a Gastroenterologist **AND**
   c. Must meet for **ONE** of the following **(A or B):**
      A. Must have tried and failed or has documented intolerance to at least ONE of the following conventional therapies for at least 3 months:
         I. Thiopurines: azathioprine/6-mercaptopurine (6-MP)
         II. 5-Aminosalicylates: sulfasalazine, mesalamine, olsalazine
         III. IV or oral steroids - note, a 3-month trial of systemic steroid therapy will not be required
      B. The patient has been diagnosed with pouchitis and has tried an antibiotic, corticosteroid enema, or mesalamine enema **AND**
   d. The patient must have had drug failure or serious side effects with **TWO** of the following: Humira/Simlandi/Hadlima, Selarsdi/Yesintek, Skyrizi, Tremfya
3. Coverage of Zeposia will be limited to:
   a. 30 capsules/30 days for Zeposia 0.92 mg capsules
   b. 7 capsules/30 days for Zeposia 7-Day Starter Pack
   c. Zeposia Starter Kit:
      i. NDC 59572-0890-91 = 37 capsules/30 days
      ii. NDC 59572-0890-28 = 28 capsules/28 days

APPROVAL TIME PERIODS:

For drugs that can be both self-administered (pharmacy benefit [Rx]) or administered by a healthcare professional (medical benefit) **OR** only administered by a healthcare professional (medical benefit), approval time frames are as follows (please refer to Policy Guidelines [#4] for approval time periods of other drugs within this policy):

Actemra/Tyenne/Avtozma (Rx/Medical), Tofidence (Medical ONLY), Cosentyx (Rx/Medical), Entyvio (Rx/Medical), Ilumya (Medical ONLY), Orencia (Rx/Medical), Simponi/Simponi Aria (Rx/Medical), Tremfya (Rx/Medical)

Line of Business	Rx Initial approval	Rx Recertification	Medical Initial approval	Medical Recertification
Commercial, Exchange, and Safety Net (Medicaid, HARP, CHP, Essential Plan)	1 year *Does not apply to Medicaid and HARP)	1 year *Does not apply to Medicaid and HARP	1 year	1 year
Medicare	Already defined in policy	Already defined in policy	2 years	2 years

POLICY GUIDELINES:

1. Utilization Management is contract dependent. Refer to specific contract/benefit language for exclusions.
   a. Coverage criteria may be dependent on the contract renewal date.

   b. Coverage of drugs listed in this policy are contract dependent.
   c. Not all contracts/benefits allow coverage of healthcare professional administered drugs as part of their pharmacy benefit.
   d. Not all contracts/benefits cover all medical infusible drugs.
   e. Not all policy criteria may apply if treatment of specific disease states or conditions is not a covered benefit.
2. This policy is subject to ongoing revision. Newly marketed drugs and existing drugs with new indications may be subject to prior authorization until formal coverage criteria are established. Inclusion of a drug in this policy does not guarantee its current availability on the market, as some agents may be discontinued, withdrawn, or otherwise unavailable. As product status changes, drugs may be removed from the policy.
3. Clinical documentation must be submitted for each request (initial and recertification [if applicable]) unless otherwise specified (e.g., provider attestation required). Supporting documentation includes, but is not limited to, progress notes documenting previous treatments and treatment history, diagnostic testing, laboratory test results, genetic testing or biomarker results, imaging and other objective or subjective measures of benefit. For recertification, continued approval requires documentation demonstrating that the requested product is providing ongoing benefit to the patient, evidenced by improvement or stability in disease state or condition, and that continued use remains medically necessary. Ongoing use of the requested product must continue align with the current policy's preferred formulary. Recertification reviews may result in a requirement to trial more cost-effective treatment alternatives as they become available (i.e., generics, biosimilars, or other guideline-supported treatment options). Requested dosing must remain consistent with FDA-approved or off-label/guideline-supported dosing recommendations.
4. This policy does not apply to Medicare Part D and D-SNP pharmacy benefits. The drugs in this policy may apply to all other lines of business including Medicare Advantage.
5. For members with Medicare Advantage, medications with a National Coverage Determination (NCD) and/or Local Coverage Determination (LCD) will be covered pursuant to the criteria outlined by the NCD and/or LCD. NCDs/LCDs for applicable medications can be found on the CMS website at https://www.cms.gov/medicare-coverage-database/search.aspx. In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS permits a Medicare Advantage Organization (MAO) to establish its own coverage determinations in accordance with 42 CFR § 422.101(b)(6). Indications that have not been addressed by the applicable medication's LCD/NCD will be covered in accordance with criteria determined by the Health Plan (which may include review per the Health Plan's Off-Label Use of FDA Approved Drugs policy). Step therapy requirements may be imposed in addition to LCD/NCD requirements.
6. This policy is based on available evidence as of the last review date. Coverage determinations are subject to applicable plan documents, state and federal regulations, and individual patient circumstances. This policy does not constitute medical advice.
7. This policy is applicable to drugs that are included on a specific drug formulary. If a drug referenced in this policy is non-formulary, please reference the Non-Formulary Medication Exception Review Policy for all Lines of Business (Pharmacy-69).
8. All requests will be reviewed to ensure they are being used for an appropriate indication and may be subject to an off-label review in accordance with our Off-Label Use of FDA Approved Drugs Policy (Pharmacy-32).
9. **Concurrent use of Inflammatory Agents**
   a. Drugs listed in this policy as well as other immunomodulating therapies or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs) not listed in this policy (Adalimumab, Enbrel, ustekinumab, Cimzia, Remicade, biosimilars, etc.) should not be administered in combination with another biologic or targeted synthetic DMARD used for an inflammatory

condition. Combination therapy is generally not recommended due to the added risk of immunosuppression, potential for a higher rate of adverse effects, and lack of evidence for additive therapy. NOTE: This does NOT exclude the use of conventional synthetic DMARDs (e.g., MTX, leflunomide, hydroxychloroquine, and sulfasalazine) in combination with biologics and targeted synthetic DMARDs.

b. Requests for the concurrent use of inflammatory agents will be evaluated for safety and efficacy and subject to off-label review.
c. Otezla/XR in combination with biologic DMARD therapy (such as adalimumab, Enbrel, Cosentyx, etc.) is not FDA approved or supported with a high level of clinically valid medical evidence for the treatment of plaque psoriasis or psoriatic arthritis. Therefore, these requests are considered combination therapy and are considered not medically necessary.

14. For commercial contracts, medical necessity determinations align with the Certificate of Coverage issued by the Health Plan, which states that covered services must be clinically appropriate and not primarily for the convenience of the member, the member's family, or the provider.
15. All utilization management requirements outlined in this policy are compliant with applicable New York State insurance laws and regulations. Policies will be reviewed and updated as necessary to ensure ongoing compliance with all state and federally mandated coverage requirements.
16. Manufacturers may either discontinue participation in, or may not participate in, the Medicaid Drug Rebate Program (MDRP). Under New York State Medicaid requirements, physician-administered drugs must be produced by manufacturers that participate in the MDRP. Products made by manufacturers that do not participate in the MDRP will not be covered under Medicaid Managed Care/HARP lines of business. Drug coverage will not be available for any product from a non-participating manufacturer. For a complete list of New/Reinstated & Terminated Labelers please visit: https://www.medicaid.gov/medicaid/prescriptiondrugs/medicaid-drug-rebate-program/newreinstated-terminated-labeler-information/index.html
17. The requested site of care may impact approval timeframe and subject to review.
18. Approval timeframes may be extended to align authorization periods for drugs administered as part of a multidrug regimen, including when regimen components are administered across different benefits. This provision does not apply when the approval timeframe reflects a drug-specific limitation on duration of therapy.

UPDATES:

Date	Revision
11/19/2026	Revised with November P&T Committee Approval
11/12/2026	P&T Committee Review and approval
09/14/2026	Revised
09/11/2026	Revised
08/13/2026	Reviewed & P&T Committee Approval
07/28/2026	Revised
07/24/2026	Revised
06/23/2026	Revised
06/15/2026	Revised
06/12/2026	Revised
06/01/2026	Revised
04/24/2026	Revised
03/26/2026	Revised
03/20/2026	Revised
02/12/2026	Reviewed & P&T Committee Approval
01/23/2026	Revised
01/01/2026	Revised

12/05/2025	Revised
11/25/2025	Revised
11/19/2025	Revised
11/13/2025	Reviewed & P&T Committee Approval
10/16/2025	Revised
10/10/2025	Revised
10/01/2025	Revised
08/27/2025	Revised
08/14/2025	Reviewed & P&T Committee Approval
08/07/2025	Revised
08/06/2025	Revised
05/08/2025	Reviewed & P&T Committee Approval
04/24/2025	Revised
04/08/2025	Revised
03/06/2024	Revised
03/01/2025	Revised
02/17/2025	Revised
02/06/2025	Revised
01/21/2025	Revised
01/06/2025	Revised
01/01/2025	Revised
12/05/2024	Revised
11/21/2024	Reviewed & P&T Committee Approval
11/19/2024	Revised
10/10/2024	Revised
10/01/2024	Revised
09/13/2024	Revised
08/29/2024	Revised
08/15/2024	Reviewed / P&T Committee Approval
08/08/2024	Revised
08/01/2024	Revised
07/12/2024	Revised
06/24/2024	Revised
06/05/2024	Revised
04/30/2024	Revised
04/18/2024	Revised
12/06/2023	Revised
11/30/2023	Revised
10/25/2023	Revised
09/01/2023	Revised
08/24/2023	P&T Committee Approval
06/23/2023	Revised
04/01/2023	Revised
03/15/2023	Revised
01/01/2023	Revised
09/2022	Revised / P&T Committee Approval
08/2022	Revised
07/2022	Revised
06/2022	Revised
05/2022	Revised
04/2022	Revised
02/2022	Revised

09/2021	Reviewed / P&T Committee Approval
08/2021	Revised
07/2021	Revised
06/2021	Revised
05/2021	Revised
04/2021	Revised
01/2021	Revised
11/2020	Revised
9/2020	Revised / P&T Committee Approval
8/2020	Revised
6/2020	Revised
5/2020	Revised
4/2020	Revised
2/2020	Revised
1/2020	Revised
9/2019	Revised
8/2019	Revised
5/2019	Revised
1/2019	Revised
10/2018	Revised
7/2018	Revised
6/2018	Revised
2/2018	Revised
1/2018	Created

APPENDIX:

Table 1: Generalized Pustular Psoriasis Physician Global Assessment (GPPGA)

Score	Erythema	Pustules	Scaling
0 (Clear)	Normal or post-inflammatory hyperpigmentation	No visible pustules	No scaling or crusting
1 (Almost Clear)	Faint, diffuse pink or slight red	Low density occasional small discrete pustules (noncoalescent)	Superficial focal scaling or crusting restricted to periphery of lesions
2 (Mild)	Light red	Moderate density grouped discrete small pustules (noncoalescent)	Predominantly fine scaling or crusting
3 (Moderate)	Bright red	High density pustules with some coalescence	Moderate scaling or crusting covering most or all lesions
4 (Severe)	Deep fiery red	Very high-density pustules with pustular lakes	Severe scaling or crusting covering most or all lesions

Each component is graded separately; the average is calculated and the final GPPGA is determined from this composite score*. A lower score indicates a lesser severity, with 0 being clear and 1 being almost clear. To receive a score of 0 or 1, the patient should be afebrile in addition to the skin presentation requirements.

*Composite mean score = (erythema + pustules + scaling)/3; total GPPGA score given is 0 if mean = 0 for all three components, 1 if mean 0 to <1.5, 2 if mean 1.5 to <2.5, 3 if mean 2.5 to <3.5, 4 if mean ≥3.5.

REFERENCES:

In addition to the full prescribing information for each individual drug, the following references have been utilized in creating drug specific criteria:

Orencia –

1. Weinblatt M. et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis & Rheumatism. August 2006; 54(9):2807-2816.
2. Kremer JM et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Annals of Internal Medicine. June 2006; 144(12):865-876.
3. Emery P. Kosinski M. Li T. Martin M. Williams GR. Becker JC. Blaisdell B. Ware JE Jr. Birbara C. Russell AS. Treatment of rheumatoid arthritis patients with abatacept and methotrexate